

**The Quarterly
Journal of Medicine**

I N D E X

OF

NEW SERIES, VOLS. XI-XX

**(VOLS. XXXV-XLIV
OF THE CONTINUOUS SERIES)**

1942-1951

AUTHOR INDEX

- Ackerman, W. L.**
'Fibrositis' of the Back, **13.** 37-51.
- Ackroyd, J. F.**
Three Cases of Thrombocytopenic Purpura occurring after Rubella, with a Review of Purpura associated with Infections, **18.** 299-318.
- Adams, E. B.**
Chronic Agranulocytosis, **18.** 173-85.
- Agius, T.**
Poliomyelitis Epidemic in Malta, 1942-3, **14.** 1-26.
- Allchin, F. M.**
Ankylosing Spondylitis, **18.** 217-34.
- Anderson, A. B.**
Loss of Weight in Obese Patients on Sub-maintenance Diets, and the Effect of Variation in the Ratio of Carbohydrate to Fat in the Diet, **13.** 27-36.
- Anderson, I. A.**
Postmenopausal Osteoporosis, Clinical Manifestations, and the Treatment with Oestrogens, **19.** 67-96.
- Andrews, G. W. S.**
Aetiology of Constrictive Pericarditis, with special reference to Tuberculous Pericarditis, together with a Note on Polyserositis, **17.** 291-321.
- Anning, S. T.**
Toxic Effects of Calciferol, **17.** 203-28.
- Arnott, W. M.**
Effect of Ephedrine in Asthma and Emphysema, **19.** 319-26.
Effect of Tobacco on Lung-Volume, **20.** 141-7.
Correlation between the Radiological Appearances and the Clinical and Spirometric State in Emphysema, **20.** 247-60.
- Baines, G. H.**
Nephrocalcinosis associated with Hyperchloraemia and Low Plasma-Bicarbonate, **14.** 113-23.
- Ball, J.**
The Kidney in Periarthritis Nodosa, **17.** 175-202.
- Balme, H. W.**
Heredity of Hypertension in Diabetes Mellitus, **20.** 335-51.
- Barber, H.**
Effects of Trauma, direct and indirect, on the Heart, **13.** 137-67.
- Barber, H. S.**
Psychogenic Basis of some so-called Rheumatic Pains, **14.** 57-74.
- Barclay, J. A.**
Nephrocalcinosis associated with Hyperchloraemia and Low Plasma-Bicarbonate, **14.** 113-23.
- Barlow, A.**
Idiopathic Pulmonary Haemosiderosis, **17.** 25-48.
- Barnes, C. G.**
Galactose Tolerance Tests in Thyrotoxicosis, **12.** 129-39.
- Beattie, J. W.**
Chronic Monocytic Leukaemia, **20.** 131-8.
- Belcher, J. R.**
Primary Staphylococcal Pneumonia, **20.** 43-55.
- Bernstein, H. G. G.**
Poliomyelitis Epidemic in Malta, 1942-3, **14.** 1-26.
- Black, A. B.**
Uraemia complicating Low Salt Treatment of Heart Failure, **20.** 149-62.
- Black, D. A. K.**
Azotaemia in Gastro-Duodenal Haemorrhage, **11.** 77-104.
Fat Absorption in Tropical Sprue, **16.** 99-109.
- Bodian, M.**
Idiopathic Pulmonary Haemosiderosis, **17.** 25-48.
- Boon, T. H.**
Aplastic Anaemia, **20.** 75-92.
- Bound, J. P.**
Fat Absorption in Tropical Sprue, **16.** 99-109.
- Brink, A. J.**
Telangiectasis of the Lungs, with Two Case Reports of Hereditary Haemorrhagic Telangiectasia with Cyanosis, **19.** 239-48.
- Brod, J.**
Origin of Oedema in Heart Failure, **19.** 187-220.
Excretion of Chlorides in Patients with Heart Failure, **19.** 221-37.
- Brown, A.**
Lead Content of Blood and its Relation to Rarefying Processes in Bone, **15.** 77-90.
Craniofacial Dysostosis: the Significance of Ocular Hypertelorism, **15.** 171-81.
- Brown, J.**
Dystrophia Myotonica: an Endocrine Study, **19.** 303-18.
- Bryson, C. C.**
Carcinoma of the Bronchus, **20.** 173-86.
- Bülbring, E.**
Reduction in Coronary Flow by Pituitary (Posterior Lobe) Extract in relation to the Action of Nicotine and to Smoking, **18.** 73-80.
- Burn, J. H.**
Reduction in Coronary Flow by Pituitary (Posterior Lobe) Extract in relation to the Action of Nicotine and to Smoking, **18.** 73-80.

- Burnard, E. D.**
Idiopathic Hyperchloraemic Renal Acidosis of Infants (Nephrocalcinosis Infantum): Observations on the Site and Nature of the Lesion, **19**, 285-301.
- Burrows, H. J.**
Spinal Osteoporosis of Unknown Origin, **14**, 147-70.
- Callender, S. T. E.**
Critical Review of Pernicious Anaemia of Pregnancy, **13**, 75-105.
- Cameron, J. D. S.**
Infective Hepatitis, **12**, 139-55.
- Campbell, M.**
Genetic and Environmental Factors in Congenital Heart Disease, **18**, 379-91.
- Carleton, A.**
Maffucci's Syndrome (Dyschondroplasia with Haemangiomas), **11**, 203-28.
Treatment of Arsenical Dermatitis with Dimercaptopropanol (BAL), **17**, 49-79.
- Carter, C. W.**
Nicotinic Acid Content of Blood in Health and Disease, **14**, 197-205.
- Cates, J. E.**
Subacute Bacterial Endocarditis, **20**, 93-130.
- Cathie, I. A. B.**
Note on the Pathology of Congenital Toxoplasmosis, **19**, 64-65.
- Caughey, J. E.**
Dystrophia Myotonica: an Endocrine Study, **19**, 303-18.
- Christie, R. V.**
Subacute Bacterial Endocarditis, **20**, 93-130.
- Cloake, P. C. P.**
Temporal Arteritis, **15**, 47-75.
- Colbeck, J. C.**
Temporal Arteritis, **15**, 47-75.
- Cole, L.**
Heredity of Hypertension in Diabetes Mellitus, **20**, 335-51.
- Cooke, W. T.**
Nephrocalcinosis associated with Hyperchloraemia and Low Plasma-Bicarbonate, **14**, 113-23.
Temporal Arteritis, **15**, 47-75.
Anomalies of Intestinal Absorption of Fat: I. The Determination and Significance of Faecal Fat, **15**, 141-55; II. The Haematology of Idiopathic Steatorrhoea, **17**, 9-24.
- Cope, C. L.**
Fibrous Dysplasia of Bone with Endocrine Disorders and Cutaneous Pigmentation (Albright's Disease), **11**, 121-54.
- Copeman, W. S. C.**
'Fibrositis' of the Back, **13**, 37-51.
- Crawford, T.**
Glycogen Disease, **15**, 285-98.
- Crowther, K. V.**
Chronic Monoeytic Leukaemia, **20**, 131-8.
- Cruickshank, E. K.**
Wernicke's Encephalopathy, **19**, 327-38.
- Cullinan, E. R.**
Description of an Outbreak of Beri-beri, **15**, 91-105.
- Dacie, J. V.**
Familial Haemolytic Anaemia (Achloric Jaundice), with particular reference to Changes in Fragility produced by Splenectomy, **12**, 101-18.
Association of Raynaud's Phenomena, Chronic Haemolytic Anaemia, and the Formation of Cold Antibodies, **20**, 275-92.
- Daley, R.**
Massive Dilatation of the Left Auricle, **18**, 81-91.
- Davidson, L. S. P.**
Effect of Liver Therapy on Erythropoiesis as observed by Serial Sternal Punctures in Twelve Cases of Pernicious Anaemia, **11**, 19-27.
Proteolysed Liver in the Treatment of Refractory Anaemias, **13**, 53-73.
- Davies, C. E.**
Heart Failure in Acute Nephritis, **20**, 163-71.
- Davies, J. H. T.**
Therapeutic Trial of Penicillin in Infective Conditions of the Skin, **14**, 183-96.
- Davis, L. J.**
Effect of Liver Therapy on Erythropoiesis as observed by Serial Sternal Punctures in Twelve Cases of Pernicious Anaemia, **11**, 19-27.
Proteolysed Liver in the Treatment of Refractory Anaemias, **13**, 53-73.
On the Nature and Significance of Stippling in Lead Poisoning, with reference to the Effect of Splenectomy, **18**, 57-72.
- Davison, P. H.**
The Influence of Intravenous Digoxin on Renal Function in Congestive Cardiac Failure, **20**, 389-401.
- Davson, J.**
The Kidney in Periarthritis Nodosa, **17**, 175-202.
Clinical and Pathological Study of Renal Disease: I. Nephritis, **18**, 149-71; II. Diseases other than Nephritis, **19**, 33-55.
- Dawson, J.**
Toxic Effects of Calciferol, **17**, 203-28.
- Dent, C. E.**
Studies on the Mechanism of the Fanconi Syndrome, **16**, 275-90.
Aminoacid Metabolism in Cystinuria, **20**, 205-19.
- Denz, F. A.**
Hunger Oedema, **16**, 1-19.
- Dick, G. W. A.**
Epidemiology of the 1945 Outbreak of Poliomyelitis in Mauritius, **15**, 183-208.

- Dick, R. C. S.**
Chronic Peptic Ulcer of the Oesophagus and its association with Congenitally Short Oesophagus and Diaphragmatic Hernia, **11**. 105-20.
- Dimsdale, H.**
Changes in the Parkinsonian Syndrome in the Twentieth Century, **15**. 155-70.
- Dimson, S. B.**
Pamaquin Haemoglobinuria, **15**. 25-46.
- Dixon, H. B. F.**
Cysticercosis (*Taenia solium*): a further Ten Years' Clinical Study, covering 284 Cases, **13**. 107-21.
- Dixon, K.**
Therapeutic Trial of Penicillin in Infective Conditions of the Skin, **14**. 183-96.
- Dolby, D. E.**
Toxic Effects of Calciferol, **17**. 203-28.
- Donaldson, G. M. M.**
Congenital Afibrinogenaemia, **14**. 101-11.
- Downie, E.**
Haemochromatosis: Observations on the Incidence and on the Value of Liver Biopsy in Diagnosis, **17**. 247-56.
- Dresner, E.**
Primary Optic Atrophy in Von Recklinghausen's Disease (Multiple Neurofibromatosis), **18**. 93-103.
Bone and Joint Lesions in Acute Leukaemia and their Response to Folic Acid Antagonists, **19**. 339-52.
- Dunlop, D. M.**
Antihistamine Drugs, **17**. 271-90.
- Eden, K. C.**
Localized Pretibial Myxoedema in association with Toxic Goitre, **11**. 229-40.
- Elkes, J. J.**
Anomalies of Intestinal Absorption of Fat: I. The Determination and Significance of Faecal Fat, **15**. 141-55.
- Elkington, J. St. C.**
Maffucci's Syndrome (Dyschondroplasia with Haemangiomas), **11**. 203-28.
- Ellman, P.**
Contribution to the Pathology of Sjögren's Disease, **20**. 33-42.
- Evans, P. R.**
Neurological Sequelae of Rh Sensitization, **19**. 129-49.
- Everard, A.**
Snake-bite by *Echis carinata*, **16**. 291-303.
- Falconer, M. A.**
Fibrous Dysplasia of Bone with Endocrine Disorders and Cutaneous Pigmentation (Albright's Disease), **11**. 121-54.
- Fejfar, Z.**
Origin of Oedema in Heart Failure, **19**. 187-220.
Excretion of Chlorides in Patients with Heart Failure, **19**. 221-37.
- Fernando, P. B.**
Infective Hepatitis and Cirrhosis of the Liver, **20**. 403-19.
- Ferriman, D. G.**
Association of Raynaud's Phenomena, Chronic Haemolytic Anaemia, and the Formation of Cold Antibodies, **20**. 275-92.
- Fisher, H. J. W.**
Congenital Toxoplasmosis, with a Note on the Pathology, **19**. 57-66.
- Fisher, J. A.**
Cryptogenic Acquired Haemolytic Anaemias, **16**. 245-62.
- Fisher, R. A.**
Genetical Note on Hereditary and Familial Aspects of Exophthalmic Goitre and Nodular Goitre, **14**. 207-19.
Hereditary and Familial Aspects of Toxic Nodular Goitre (Secondary Thyrotoxicosis), **20**. 293-7.
- Flind, J.**
Psychogenic Basis of some so-called Rheumatic Pains, **14**. 57-74.
- Fourman, L. P. R.**
Fat Absorption in Tropical Sprue, **16**. 99-109.
- Franks, R.**
Massive Dilatation of the Left Auricle, **18**. 81-91.
- Frazer, A. C.**
Anomalies of Intestinal Absorption of Fat: I. The Determination and Significance of Faecal Fat, **15**. 141-55; II. The Haematology of Idiopathic Steatorrhoea, **17**. 9-24.
- Fullerton, J. M.**
Association of Raynaud's Phenomena, Chronic Haemolytic Anaemia, and the Formation of Cold Antibodies, **20**. 275-92.
- Gaddie, R.**
The Influence of Intravenous Digoxin on Renal Function in Congestive Cardiac Failure, **20**. 389-401.
- Gairdner, D.**
Schönlein-Henoch Syndrome (Anaphylactoid Purpura), **17**. 95-122.
- Geoghegan, H.**
Cholinesterase Activity of Blood and Muscle in Myasthenia Gravis, **20**. 13-19.
Cholinesterase Inhibition and Signs and Symptoms in Myasthenia Gravis, **20**. 21-31.
- Gibson, M. O. J.**
Primary Staphylococcal Pneumonia, **20**. 43-55.
- Gillanders, A. D.**
Circulatory Dynamics in Emphysema, **18**. 263-73.
- Goodier, T. E. W.**
Contribution to the Pathology of Sjögren's Disease, **20**. 33-42.

- Goodwin, J. F.**
Use of Radioactive Iodine in the Assessment of Thyroid Function, **20**. 353-87.
- Govan, A. D. T.**
Temporal Arteritis, **15**. 47-75.
Nephrocalcinosis associated with Hyperchloraemia and Low Plasma-Bicarbonate, **19**. 277-83.
- Graham, G.**
Spinal Osteoporosis of Unknown Origin, **14**. 147-70.
Treatment of Spontaneous Hypoglycaemia due to Hyperplasia of the Islets of Langerhans, **19**. 21-31.
- Graham, J. D. P.**
Toxic Manifestations of Sodium Salicylate Therapy, **17**. 153-63.
- Gray, C. H.**
Significance of the Van den Bergh Reaction, **16**. 135-42.
Case of Chronic Porphyria associated with Recurrent Jaundice, **17**. 123-37.
Changes in Liver Function during Liver Disease, **19**. 263-76.
- Greenfield, J. G.**
Maffucci's Syndrome (Dyschondroplasia with Haemangiomas), **11**. 203-28.
- Greenwood, M.**
Treatment of Post-Arsphenamine Jaundice with Sulphur-containing Amino acids, **14**. 35-56.
- Hall, G. S.**
Contribution to the Study of Melorheostosis: Unusual Bone Changes associated with Tuberosc Sclerosis, **12**. 77-100.
Ocular Manifestations of Tuberosc Sclerosis, **15**. 209-20.
- Hargreaves, W. H.**
Cysticercosis (*Taenia solium*): a further Ten Years' Clinical Study, covering 284 cases, **13**. 107-21.
Treatment of Amoebiasis with special reference to Chronic Amoebic Dysentery, **15**. 1-23.
- Harper, R. K.**
Craniofacial Dysostosis: the Significance of Ocular Hypertelorism, **15**. 171-81.
- Hart, F. D.**
Ankylosing Spondylitis, **18**. 217-34.
- Henderson, J. L.**
Congenital Afibrinogenemia, **14**. 101-11.
- Herbert, F. K.**
Estimation of Prostatic Phosphatase in Serum, and its Use in the Diagnosis of Prostatic Carcinoma, **15**. 221-41.
- Herson, R. N.**
Ocular Manifestations of Polyarteritis Nodosa, **18**. 123-32.
- Hickey, M. D.**
Chronic Haemolytic Anaemia with Haemoglobinuria, **17**. 1-8.
- Hickie, G.**
Experimental Observations on Chronic Agranulocytosis, **17**. 165-74.
- Higgins, G.**
Ascites in Chronic Disease of the Liver, **16**. 263-74.
- Hoyle, C.**
Artificial Pneumothorax, **20**. 313-34.
- Hubble, D.**
Cushing's Syndrome and Thymic Carcinoma, **18**. 133-47.
- Humble, J. G.**
Aetiology of Chloroma, and the Nature of the Green Pigment, **15**. 299-312.
- Hunter, A.**
The Heart in Anaemia, **15**. 107-24.
- Hunter, D.**
Industrial Toxicology, **12**. 185-258.
- Hunter, R. B.**
Antihistamine Drugs, **17**. 271-90.
- Hurst, A.**
Chronic Peptic Ulcer of the Oesophagus and its association with Congenitally Short Oesophagus and Diaphragmatic Hernia, **11**. 105-20.
- Hutchison, J. H.**
Bronchoscopic Studies on Primary Tuberculosis in Childhood, **18**. 21-49.
- Hutchison, R.**
William Osler, **18**. 275-7.
- Hutt, M. S. R.**
Felty's Syndrome: Four Cases Treated by Splenectomy, **20**. 57-73.
- Ingram, J. T.**
Toxic Effects of Calciferol, **17**. 203-28.
- Innes, J.**
Effect of Liver Therapy on Erythropoiesis as observed by Serial Sternal Punctures in Twelve Cases of Pernicious Anaemia, **11**. 19-27.
- Jones, A. M.**
Methyl Chloride Poisoning, **11**. 29-43.
- Keele, K. D.**
Association of Raynaud's Phenomena, Chronic Haemolytic Anaemia, and the Formation of Cold Antibodies, **20**. 275-92.
- Kekwick, A.**
Description of an Outbreak of Beri-beri, **15**. 91-105.
- Kelsall, A. R.**
Ascites in Chronic Disease of the Liver, **16**. 263-74.
- Kendall, D.**
Aetiology, Diagnosis, and Treatment of Prolapsed Intervertebral Disk, with a Review of 300 Cases of Sciatica, **16**. 157-79.
- King, A. J.**
Treatment of Post-Arsphenamine Jaundice with Sulphur-containing Amino acids, **14**. 35-56.

- King, E. J.**
Galactose Tolerance Tests in Thyrotoxicosis, **12**. 129-39.
- King, W. E.**
Haemochromatosis: Observations on the Incidence and on the Value of Liver Biopsy in Diagnosis, **17**. 247-56.
- Langley, G. J.**
Hypertension and Unilateral Kidney Disease, **16**. 143-55.
- Latner, A. L.**
Ankylosing Spondylitis, **18**. 187-201.
Idiopathic Hyperchloraemic Renal Acidosis of Infants (Nephrocalcinosis Infantum): Observations on the Site and Nature of the Lesion, **19**. 285-301.
- Lawrence, R. D.**
Pregnancy and Diabetes, **11**. 45-75.
Pathological Changes in the Brain in Fatal Hypoglycaemia, **11**. 181-201.
- Leatham, A.**
Retinal Vessels in Hypertension, **18**. 203-15.
- Leishman, A. W. D.**
Electrocardiogram in Hypertension, **20**. 1-12.
- Lendrum, A. C.**
Pulmonary Changes due to Cardiac Disease, with special reference to Haemosiderosis, **19**. 249-62.
- Lennox, B.**
Association of Bronchial Carcinoma and Peripheral Neuritis, **19**. 97-109.
- Lewis, F. J. W.**
Pneumonia in Infants, Children, and Adults, **11**. 155-80.
- Lipscomb, J. M.**
Elliptocytosis in Man associated with Hereditary Haemorrhagic Telangiectasia, **12**. 157-69.
- Litchfield, J. A.**
Uraemia complicating Low Salt Treatment of Heart Failure, **20**. 149-62.
- Lubran, M.**
Potassium Deficiency in Ulcerative Colitis, **20**. 221-32.
- Luxton, R. W.**
Pneumococcal Endocarditis, **12**. 61-75.
- Lyall, A.**
Classification of Cases of Glycosuria, **15**. 243-53.
- McAllen, P. M.**
Potassium Deficiency in Ulcerative Colitis, **20**. 221-32.
- McCance, R. A.**
Osteomalacia with Looser's Nodes (Milkman's Syndrome) due to a Raised Resistance to Vitamin D acquired about the Age of 15 Years, **16**. 33-46.
- McFadzean, A. J. S.**
On the Nature and Significance of Stippling in Lead Poisoning with reference to the Effect of Splenectomy, **18**. 57-72.
- McFarlan, A. M.**
Epidemiology of Infective Hepatitis in some Units of the British Army in Sicily and Great Britain, 1943-4, **14**. 125-46.
Epidemiology of the 1945 Outbreak of Poliomyelitis in Mauritius, **15**. 183-208.
- McGeorge, M.**
Renal Function and Prognosis in Benign Hypertension, **14**. 171-82.
Results of Treatment of Gastric Hyperacidity by Radium, with special reference to Duodenal Ulceration, **19**. 111-28.
- Macgregor, A. G.**
Use of Radioactive Iodine in the Assessment of Thyroid Function, **20**. 353-87.
- MacLagan, N. F.**
Ankylosing Spondylitis, **18**. 217-34.
- McMartin, R. B.**
Pamaquin Haemoglobinuria, **15**. 25-46.
- McMichael, J.**
Action of Intravenous Digoxin in Man, **13**. 123-35.
- Malley, L. K.**
Chronic Haemolytic Anaemia with Haemoglobinuria, **17**. 1-8.
- Marks, J.**
Marchiafava Micheli Syndrome, **18**. 105-21.
- Martin, L.**
Results of X-Ray Therapy in Thyrotoxicosis, **11**. 1-17.
Hereditary and Familial Aspects of Exophthalmic Goitre and Nodular Goitre, **14**. 207-19.
Hereditary and Familial Aspects of Toxic Nodular Goitre (Secondary Thyrotoxicosis), **20**. 293-7.
- Martin, W. J.**
Treatment of Post-Arsphenamine Jaundice with Sulphur-containing Aminoacids, **14**. 35-56.
- Marxer, O. A.**
Polyps of the Stomach and Polypoid Gastritis, **12**. 1-60.
- Maw, G. A.**
Cholinesterase Activity of Blood and Muscle in Myasthenia Gravis: **20**. 13-19.
Cholinesterase Inhibition and Signs and Symptoms in Myasthenia Gravis, **20**. 21-31.
- Merskey, C.**
Occurrence of Haemophilia in the Human Female, **20**. 299-312.
- Meulengracht, E.**
Review of Chronic Intermittent Juvenile Jaundice, **16**. 83-98.
- Meyer, A.**
Pathological Changes in the Brain in Fatal Hypoglycaemia, **11**. 181-201.
- Middlemiss, J. H.**
Ankylosing Spondylitis, **18**. 187-201.

- Miller, A. A.**
Outbreak of Severe Infective Hepatitis in Burma, 16. 211-36.
- Miller, H.**
Use of Radioactive Iodine in the Assessment of Thyroid Function, 20. 353-87.
- Miller, H. G.**
Clinical Aspects of Polyarteritis Nodosa, 15. 255-83.
- Mole, R. H.**
Snake-bite by *Echis carinata*, 16. 291-303.
- Montgomery, D. A. D.**
Primary Optic Atrophy in Von Recklinghausen's Disease (Multiple Neurofibromatosis), 18. 93-103.
- Mowbray, R.**
Ankylosing Spondylitis, 18. 187-201.
- Muir, A.**
Carbohydrate Metabolism and Gastric Secretory Activity, 18. 235-61.
- Nevin, S.**
Pathological Changes in the Brain in Fatal Hypoglycaemia, 11. 181-201.
- Nicholson, H.**
Artificial Pneumothorax, 20. 313-34.
- Nicol, C. S.**
Treatment of Post-Arsphenamine Jaundice with Sulphur-containing Amino acids, 14. 35-56.
- Oakley, W. G.**
Pregnancy and Diabetes, 11. 45-75.
Treatment of Spontaneous Hypoglycaemia due to Hyperplasia of the Islets of Langerhans, 19. 21-31.
- O'Brien, J. R. P.**
Nicotinic Acid Content of Blood in Health and Disease, 14. 197-205.
Ascites in Chronic Disease of the Liver, 16. 263-74.
- Ormiston, G.**
Pneumonia in Infants, Children, and Adults, 11. 155-80.
- Oswald, N.**
Honeycomb Lungs, 18. 1-20.
- Pallister, R. A.**
Oedema in an Internment Camp, 16. 47-60.
- Pappenheimer, A. M.**
Anaemia associated with Unidentified Erythrocytic Inclusions after Splenectomy, 14. 75-100.
- Park, S. D. S.**
Pulmonary Changes due to Cardiac Disease, with special reference to Haemosiderosis, 19. 249-62.
- Parker, D. D.**
Anaemia associated with Unidentified Erythrocytic Inclusions after Splenectomy, 14. 75-100.
- Parker, W. A.**
Toxic Manifestations of Sodium Salicylate Therapy, 17. 153-63.
Factors influencing Plasma Concentrations of Salicylate, 17. 229-46.
- Parkes, J.**
Anomalies of Intestinal Absorption of Fat: I. The Determination and Significance of Faecal Fat, 15. 141-55.
- Parkinson, T.**
Honeycomb Lungs, 18. 1-20.
- Paton, J. H. P.**
Tonsil-Adenoid Operation in relation to the Health of a Group of School-Girls, 12. 119-28.
- Peeney, A. L. P.**
Anomalies of Intestinal Absorption of Fat: I. The Determination and Significance of Faecal Fat, 15. 141-55; II. The Haematology of Idiopathic Steatorrhoea, 17. 9-24.
- Penfold, J. B.**
Elliptocytosis in Man associated with Hereditary Haemorrhagic Telangiectasia, 12. 157-69.
- Peters, R. A.**
Treatment of Post-Arsphenamine Jaundice with Sulphur-containing Amino acids, 14. 35-56.
Treatment of Arsenical Dermatitis with Dimercaptopropanol (BAL), 17. 49-79.
- Pickering, G. W.**
Aetiology of Constrictive Pericarditis, with special reference to Tuberculous Pericarditis, together with a Note on Polyserositis, 17. 291-321.
- Platt, R.**
Heredity in Hypertension, 16. 111-33.
Hypertension and Unilateral Kidney Disease, 16. 143-55.
Severe Hypertension in Young Persons, 17. 83-93.
Kidney in Periarteritis Nodosa, 17. 176-202.
Clinical and Pathological Study of Renal Disease: I. Nephritis, 18. 149-71; II. Diseases other than Nephritis, 19. 33-55.
- Polani, P. E.**
Neurological Sequelae of Rh Sensitization, 19. 129-49.
- Powell, J. F.**
Serum-Iron in Health and Disease, 13. 19-26.
- Prichard, S.**
Association of Bronchial Carcinoma and Peripheral Neuritis, 19. 97-109.
- Reid, J.**
Mepacrine and Falciparum Malaria, 16. 61-82.
Does Sodium Salicylate Cure Rheumatic Fever? 17. 139-51.
Mode of Action of Salicylate in Acute Rheumatic Fever, 19. 1-19.
- Rennie, J. B.**
Oedematous Syndrome of Nephritis, with special reference to Prognosis, 16. 21-31.

- Richards, D. G. B.**
Correlation between the Radiological Appearances and the Clinical and Spirometric State in Emphysema, **20**, 247-60.
- Richardson, J. S.**
Felty's Syndrome: Four Cases treated by Splenectomy, **20**, 57-73.
- Rimington, C.**
Case of Chronic Porphyria associated with Recurrent Jaundice, **17**, 123-37.
- Robb-Smith, A. H. T.**
Maffucci's Syndrome (Dyschondroplasia with Haemangiomas), **11**, 203-28.
- Roberts, J. A. Fraser**
Genetic Linkage in Man, with particular reference to the Usefulness of Very Small Bodies of Data, **14**, 27-33.
- Robinson, K. C.**
Ankylosing Spondylitis, **18**, 217-34.
- Robson, H. N.**
Idiopathic Thrombocytopenic Purpura, **18**, 279-97.
- Rook, A. F.**
Fainting and Flying, **16**, 181-209.
- Roscoe, M. H.**
Biochemical and Haematological Changes in Type 1 and Type 2 Nephritis, **19**, 161-86.
- Rose, G. A.**
Aminoacid Metabolism in Cystinuria, **20**, 205-19.
- Sammons, H. G.**
Anomalies of Intestinal Absorption of Fat: I. The Determination and Significance of Faecal Fat, **15**, 141-55; II. The Haematology of Idiopathic Steatorrhoea, **17**, 9-24.
- Sampson, R.**
Ocular Manifestations of Polyarteritis Nodosa, **18**, 123-32.
- Scadding, F.**
Artificial Pneumothorax, **20**, 313-34.
- Scarborough, H.**
Congenital Afibrinogenemia, **14**, 101-11.
- Scott, L. D. W.**
Pulmonary Changes due to Cardiac Disease, with special reference to Haemosiderosis, **19**, 249-62.
- Seal, R. M. E.**
Chronic Monocytic Leukaemia, **20**, 131-38.
- Seddon, H. J.**
Poliomyelitis Epidemic in Malta, 1942-3, **14**, 1-26.
Epidemiology of the 1945 Outbreak of Poliomyelitis in Mauritius, **15**, 183-208.
- Sellors, T. H.**
Aetiology of Constrictive Pericarditis, with special reference to Tuberculous Pericarditis, together with a Note on Polyserositis, **17**, 291-321.
- Seville, R.**
Senile Purpura, **19**, 151-59.
- Sharpey-Schafer, E. P.**
Action of Intravenous Digoxin in Man, **13**, 123-35.
- Sheehan, H. L.**
Syndrome of Hypopituitarism, **18**, 319-78.
- Sheldon, W.**
Idiopathic Pulmonary Haemosiderosis, **17**, 25-48.
- Short, D. S.**
Radiological Study of Pulmonary Infarction, **20**, 233-45.
- Smart, J.**
Complete Congenital Agenesis of a Lung, **15**, 125-39.
- Smith, G. S.**
Pneumococcal Endocarditis, **12**, 61-75.
- Smith, K. E.**
Anaemia associated with Unidentified Erythrocytic Inclusions after Splenectomy, **14**, 75-100.
- Smith, O. E.**
Correlation between the Radiological Appearances and the Clinical and Spirometric State in Emphysema, **20**, 247-60.
- Spencer, H.**
Carcinoma of the Bronchus, **20**, 173-86.
- Spriggs, E. I.**
Polyps of the Stomach and Polypoid Gastritis, **12**, 1-60.
- Sproull, D. H.**
Mode of Action of Salicylate in Acute Rheumatic Fever, **19**, 1-19.
- Staffurth, J. S.**
Felty's Syndrome: Four Cases treated by Splenectomy, **20**, 57-73.
- Stewart, A. M.**
Ascites in Chronic Disease of the Liver, **16**, 263-74.
- Stokes, J. F.**
Outbreak of Severe Infective Hepatitis in Burma, **16**, 211-36.
- Stoner, H. B.**
Myasthenia Gravis: a Consideration of its Causation in a Study of 14 Cases, **13**, 1-18.
Effect of the Injection of Acetylcholine into the Brachial Artery of Normal Subjects and Patients with Myasthenia Gravis, **16**, 237-43.
- Stowers, J. M.**
Studies on the Mechanism of the Fanconi Syndrome, **16**, 275-90.
- Stuart-Harris, C. H.**
Therapeutic Trial of Penicillin in Infective Conditions of the Skin, **14**, 183-96.
- Summers, V. K.**
Syndrome of Hypopituitarism, **18**, 319-78.
- Tattersall, R. N.**
Senile Purpura, **19**, 151-9.

- Thanabalasunderam, R. S.**
Infective Hepatitis and Cirrhosis of the Liver, 20. 403-19.
- Thomas, G.**
Anomalies of Intestinal Absorption of Fat: I. The Determination and Significance of Faecal Fat, 15. 141-55.
- Thompson, M. D.**
Anomalies of Intestinal Absorption of Fat: II. The Haematology of Idiopathic Steatorrhoea, 17. 9-24.
- Thompson, R. B.**
Megalo-blastic Anaemia of Pregnancy and the Puerperium, 20. 187-204.
- Thompson, R. H. S.**
Treatment of Post-Arsphenamine Jaundice with Sulphur-containing Amino-acids, 14. 35-56.
Treatment of Arsenical Dermatitis with Dimercaptopropanol (BAL), 17. 49-79.
- Thompson, W. P.**
Anaemia associated with Unidentified Erythrocytic Inclusions after Splenectomy, 14. 75-100.
- Thomson, S.**
Case of Chronic Porphyria associated with Recurrent Jaundice, 17. 123-37.
- Thomson, W. W. D.**
Sir William Osler, 18. 403-4.
- Titman, W. L.**
Description of an Outbreak of Beri-beri, 15. 91-105.
- Trotter, W. R.**
Localized Pretibial Myxoedema in Association with Toxic Goitre, 11. 229-40.
- Tunbridge, R. E.**
Pathological and Clinical Findings in Blast Injury, 12. 169-84.
Poliomyelitis Epidemic in Malta, 1942-3, 14. 1-26.
- Ungley, C. C.**
Megalo-blastic Anaemia of Pregnancy and the Puerperium, 20. 187-204.
- Viswanathan, R.**
Pulmonary Eosinophilosis, 17. 257-70.
- Walker, J. M.**
Effect of Smoking on Water Diuresis in Man, 18. 51-55.
Reduction in Coronary Flow by Pituitary (Posterior Lobe) Extract in relation to the Action of Nicotine and to Smoking, 18. 73-80.
- Walshe, J. M.**
Observations on the Symptomatology and Pathogenesis of Hepatic Coma, 20. 421-38.
- Walton, J. N.**
Aplastic Anaemia, 20. 75-92.
- Waterhouse, J. A. H.**
Effect of Ephedrine in Asthma and Emphysema, 19. 319-26.
Effect of Tobacco on Lung-Volume, 20. 141-7.
Correlation between the Radiological Appearances and the Clinical and Spirometric State in Emphysema, 20. 247-60.
- Watson, R. D.**
Mode of Action of Salicylate in Acute Rheumatic Fever, 19. 1-19.
- Watts, A. S.**
Description of an Outbreak of Beri-beri, 15. 91-105.
- Wayne, E. J.**
Use of Radioactive Iodine in the Assessment of Thyroid Function, 20. 353-87.
- Weber, F. P.**
Remarks concerning Chronic Jaundice, 17. 81.
Contribution to the Pathology of Sjögren's Disease, 20. 33-42.
- Whitfield, A. G. W.**
Effect of Ephedrine in Asthma and Emphysema, 19. 319-26.
Effect of Tobacco on Lung-Volume, 20. 141-7.
Correlation between the Radiological Appearances and the Clinical and Spirometric State in Emphysema, 20. 247-60.
- Williams, D. I.**
Treatment of Post-Arsphenamine Jaundice with Sulphur-containing Amino-acids, 14. 35-56.
- Wilson, A.**
Myasthenia Gravis: a Consideration of its Causation in a Study of 14 Cases, 13. 1-18.
Effect of the Injection of Acetylcholine into the Brachial Artery of Normal Subjects and Patients with Myasthenia Gravis, 16. 237-43.
Cholinesterase Activity of Blood and Muscle in Myasthenia Gravis, 20. 13-19.
Cholinesterase Inhibition and Signs and Symptoms in Myasthenia Gravis, 20. 21-31.
- Wilson, J. V.**
Pathological and Clinical Findings in Blast Injury, 12. 169-84.
- Witts, L. J.**
Ascites in Chronic Disease of the Liver, 16. 263-74.
Chronic Agranulocytosis, 18. 173-85.
- Wolff, H. H.**
Mechanism and Significance of the Cold Pressor Response, 20. 261-73.
- Woodman, D.**
Pneumonia in Infants, Children, and Adults, 11. 155-80.
- Wyllie, W. G.**
Idiopathic Pulmonary Haemosiderosis, 17. 25-48.
Congenital Toxoplasmosis, with a Note on the Pathology, 19. 57-66.

SUBJECT INDEX

- Abdominal distension:** in hepatitis, 16. 216.
- Abdominal symptoms:** in blast injury, 12. 179-80; in polyarteritis nodosa, 15. 267-71.
- Abortion:** threatened, and congenital heart disease, 18. 388.
- Absorption of fat:** in tropical sprue, 16. 99-109.
- Acetylcholine:** in myasthenia gravis, 13. 3-12, 16. 237-43, 20. 13-19.
- Achlorhydria:** and osteoporosis, 14. 156, 164, 19. 68.
- Acholuric jaundice** (familial haemolytic anaemia): 12. 101-18; 20. 288; pathogenesis of, 12. 112-16.
- Acidosis:** idiopathic renal, of infants, 19. 285-301.
- Acromegaly:** 20. 367.
- Action of salicylate** in acute rheumatic fever, 19. 1-19.
- Acute haemolytic anaemia:** 16. 255-6.
- hepatitis: 16. 223-5, 19. 268-71, 20. 404-6, 414.
 - infections: thrombocytopenia in, 18. 309.
 - leukaemia: bone and joint lesions in, 19. 339-52.
 - nephritis: heart failure in, 20. 163-71. *See also* Nephritis.
 - rheumatic fever: action of salicylate in, 19. 1-19.
- Acyanotic congenital heart disease,** 18. 382, 389.
- Addison's disease:** 18. 345, 355.
- Adenoids:** tonsil-adenoid operation in relation to the health of a group of school-girls, 12. 119-28.
- Adenoma:** toxic. *See* Toxic nodular goitre.
- Adrenal function:** in Cushing's syndrome, 18. 133-5, 141-5; in dystrophia myotonica, 19. 313-15.
- gland: in hypopituitarism, 18. 335.
- Aetiology of chloroma** and the nature of the green pigment: 15. 299-312.
- Afibrinogenaemia:** congenital, 14. 101-11.
- Agranulocytosis:** chronic, 18. 173-85; experimental observations, 17. 165-74.
- Albright's disease:** 11. 121-54.
- Alcohol:** in infective hepatitis and cirrhosis of the liver, 20. 413.
- Alkalies:** and osteoporosis, 14. 155-6.
- Alkalosis:** respiratory, in salicylate therapy, 17. 158-62, 19. 7-9.
- Allergy:** and fainting, 16. 198; alimentary, 17. 283-4, 286-7.
- Alloxan:** 19. 26.
- Aminoacid metabolism:** in cystinuria, 20. 205-19; in liver failure, 20. 427-31.
- Aminoacids,** sulphur-containing: treatment of post-arsphenamine jaundice with, 14. 35-56.
- Amoebiasis:** 15. 1-23.
- Amyloid disease:** renal, 19. 47.
- Anaemia:** associated with unidentified erythrocytic inclusions, after splenectomy, 14. 75-100; and infective hepatitis, 20. 416; in Felty's syndrome, 20. 65-66; cerebral, 16. 191-6; heart in: 15. 107-24; hypopituitarism and, 18. 347-8; in nephritis, 19. 166-70, 182-3; serum-iron in, 13. 22.
- acute haemolytic: 16. 255-6.
 - aplastic: 20. 75-92.
 - chronic haemolytic: with haemoglobinuria, 16. 258-9, 17. 1-8, 18. 105-21, 20. 275-92.
 - cryptogenic acquired haemolytic: 16. 245-62.
 - familial haemolytic. *See* Acholuric jaundice.
 - idiopathic hypoplastic: 13. 66-7.
 - Lederer's: 16. 255-6.
 - macrocytic: 13. 54-67; in tropical and subtropical countries, 13. 95-97.
 - megaloblastic: 13. 54-62.
 - of pregnancy and the puerperium: 13. 75-105, 20. 187-204.
 - pernicious, Addisonian: 13. 67, 68, 72; blood lead in, 15. 85, 86; effect of liver therapy on erythropoiesis in, 11. 19-27; gastric polyps and, 12. 9-10.
 - of pregnancy, 13. 75-105, 20. 187-204.
 - refractory: proteolysed liver in the treatment of, 13. 53-73.
- Anaphylactoid purpura:** 17. 95-122.
- Anaphylaxis:** and histamine, 17. 271.
- Anayodin:** 15. 6-7.
- Aneurin.** *See* Vitamin B₁₂.
- Angina of effort:** 13. 153-7.
- Angioma of a vertebra,** 14. 166.
- Angioneurotic oedema:** effect of anti-histamine drugs in, 17. 283-4.
- Aniline poisoning:** in industry, 12. 227-31.
- Ankylosing spondylitis:** 14. 165, 18. 187-201, 217-34.
- Anomalies** of intestinal absorption of fat: 1. Faecal fat, 15. 141-55; 2. Haematology of idiopathic steatorrhoea, 17. 9-24.
- Anoxia, tissue:** causing azotaemia, 11. 90-91.
- Antergan:** 17. 274-5.
- Anterior poliomyelitis:** in Albright's disease, 11. 150. *See also* Poliomyelitis.
- Anthisan:** 17. 274-87.

- Antihistamine drugs:** 17. 271-90.
Aplastic anaemia: 20. 75-92.
Arginine: 20. 208-13.
Aromatic compounds: in industrial toxicology, 12. 212-37.
Arrhythmia, cardiac: from trauma, 13. 157-61; in subacute bacterial endocarditis, 20. 112.
Arsenic: 14. 37-9; poisoning in industry, 12. 201-3.
Arsenical compounds: in amoebiasis, 15. 8-9.
 — **dermatitis:** treatment of, with dimercaptopropanol, 17. 49-79.
Arseniuretted hydrogen poisoning: in industry, 12. 203-5.
Arteritis: temporal, 15. 47-75.
Arthritis: 14. 164.
 — **rheumatoid,** 18. 197; 20. 57-73.
Artificial pneumothorax: 20. 313-34; division of adhesions, 20. 319-20; atelectasis, 20. 319-21, 329; pleural effusions, 20. 319-22, 329; closure of cavities, 20. 322-5; abandonment of, 20. 324-7; results, 20. 327-31.
Ascites: in hepatitis, 16. 216-17; in chronic disease of the liver, 16. 263-74.
Asthma: treatment with antihistamine drugs, 17. 285-6.
 — **and emphysema:** effect of ephedrine in, 19. 319-26.
Atelectasis: 20. 320-1.
 — **linear,** 20. 238, 242.
Auricle, left: massive dilatation of, 18. 81-91.
Auricular fibrillation: 13. 157-8, 164, 18. 85, 20. 112.
 — **flutter:** 13. 158.
Azobillirubin: 16. 135-7.
Azotaemia: in gastro-duodenal haemorrhage, 11. 77-104; in nephritis, 16. 24-25.

Back: fibrositis of, 13. 37-51.
Backache: in ankylosing spondylitis, 18. 192, 217-18.
Bacterial endocarditis: subacute, 20. 93-130.
BAL = Dimercaptopropanol, q.v.
Bartonella: 14. 94-95.
Basal metabolic rate: and thyroid function, 20. 360-69.
Benadryl: 17. 274-87.
Benign hypertension: renal function and prognosis in, 14. 171-82; renal disease in, 19. 40-41.
Benzene poisoning: in industry, 12. 212-16.
Beri-beri: description of an outbreak of, 15. 91-105; in an internment camp, 16. 48-56; and encephalopathy, 19. 327-38.
Beryllium: in industrial toxicology, 12. 187.
Bicarbonate: reabsorption, in renal acidosis, 19. 290-97.

Biliary cirrhosis: 20. 405, 417; honey-comb lungs in, 18. 4-5.
Bilirubin. *See* Serum-bilirubin.
Biochemical and haematological changes in nephritis, 19. 161-86.
Bismuth salts in amoebiasis, 15. 9.
Blackwater fever: 15. 39-40, 43.
'Blanket treatment': in pamaquin haemoglobinuria, 15. 34-35.
Blast injury: pathological and clinical findings in, 12. 169-84.
Blood: in azotaemia, 11. 80-85; in chronic agranulocytosis, 18. 173-85; in glycogen disease, 15. 289-94; in infective hepatitis, 12. 144, 150; lead content, 15. 77-90; in nephritis, 19. 161-85, 20. 169; nicotinic acid content of, in health and disease, 14. 197-205; in pamaquin haemoglobinuria, 15. 29-31; in pernicious anaemia of pregnancy, 13. 78-82, 20. 190-4, 198-200; in postmenopausal osteoporosis, 19. 70-82; in senile purpura, 19. 153.
 — **and muscle** in myasthenia gravis: cholinesterase activity of, 20. 13-19.
 — **cholesterol:** in nephritis, 19. 174, 178.
 — **counts** in chronic agranulocytosis, 18. 180.
 — **cultures:** in subacute bacterial endocarditis, 20. 101-3, 109, 124-7.
 — **mepacrine:** 16. 68-70, 77.
 — **-pressure:** in blast injury, 12. 175-6; and cold pressor test, 20. 261-73; and fainting, 16. 191; in diabetes, 20. 336-7; in temporal arteritis, 15. 53-5.
 — **transfusion:** in ankylosing spondylitis, 18. 230; in aplastic anaemia, 20. 81-91; in acquired haemolytic anaemia, 16. 255, 259.
 — **urea:** in haematemesis, 11. 77-93; in Type 2 nephritis, 16. 26, 19. 176-9; in salt depletion, 20. 152-6.
Body growth: in dystrophia myotonica, 19. 310.
 — **water:** and salicylate therapy, 19. 13-15; and heart failure, 19. 188-205; *see also* Oedema.
 — **-weight:** in nephritis, 19. 165, 174-5; loss of, in obesity, 13. 27-36.
Bone: fibrous dysplasia of, 11. 121-54; rarefying processes in, in relation to lead content of blood, 15. 77-90.
 — **changes:** unusual, with tuberosc sclerosis, 12. 77-100; *see also* Osteomalacia; Osteoporosis; Spondylitis.
 — **and joint lesions** in acute leukaemia and their response to folic acid antagonists, 19. 339-52.
 — **-marrow:** in aplastic anaemia, 20. 76, 77, 81; in chronic agranulocytosis, 18. 181-3; in chronic monocytic leukaemia, 20. 136-7; in idiopathic steatorrhoea, 17. 14-16; in pernicious anaemia under treatment, 11. 19-26; in pernicious anaemia of pregnancy, 13. 82-4, 20. 192.

- Bone, diseases involving:** and hypopituitarism, 18. 337; and osteoporosis, 14. 165.
— **metastases:** blood lead in, 15. 81-83.
- Brachial artery** of normal subjects and patients with myasthenia gravis, effect of injection of acetylcholine into, 16. 237-43.
- Brain:** pathological changes in, in fatal hypoglycaemia, 11. 181-201; in hepatitis, 16. 227; in kernicterus, 19. 136-40.
- Breast-feeding:** in diabetic mothers, 11. 56.
- British Anti-Lewisite = Dimercaptopropanol**, q.v.
- Bronchial carcinoma** and peripheral neuritis: association of, 19. 97-109.
- Bronchitis:** 14. 142.
- Bronchoscopic studies:** in primary tuberculosis in childhood, 18. 21-49.
- Bronchoscopy:** technique of, 18. 28-9.
- Bronchus:** carcinoma of, 20. 173-86.
- Brown induration:** of the lungs, essential, 17. 25-48.
- Bullae:** in emphysema, 20. 254.
- Burma:** outbreak of severe infective hepatitis in, 16. 211-36.
- Cachexia:** 18. 338-42.
- Cadaverine:** 20. 216.
- Cadmium:** in industrial toxicology, 12. 187.
- Calciferol:** toxic effects of, 17. 203-28.
- Calcification:** heterotopic, 14. 158.
- Calcium:** 14. 167; balances in postmenopausal osteoporosis, 19. 70-85; in osteomalacia, 16. 37.
- Carbarsone:** 15. 8-9.
- Carbohydrate:** and loss of weight in obese patients, 13. 27-35.
— **metabolism:** in glycogen disease, 15. 289-94; and gastric secretory activity, 18. 235-61; and spontaneous hypoglycaemia, 19. 21-2.
- Carbon tetrachloride:** poisoning in industry, 12. 241-3.
- Carcinoma, bronchial:** association of peripheral neuritis and, 19. 97-109.
— **of the bronchus:** 20. 173-86.
— **prostatic:** diagnosis of, 15. 221-41.
— **thymic:** Cushing's syndrome and, 18. 133-47.
- Cardiac disease:** pulmonary changes due to, 19. 249-62. *See also* Heart disease.
— **disorders:** resulting from trauma, 13. 137-53; occasionally attributable to trauma, 13. 153-64.
— **failure:** congestive: influence of intravenous digoxin on renal function in, 20. 389-401. *See also* Heart failure.
— **overstrain:** primary, 13. 151-3.
- Casein:** in treatment of post-arsphenamine jaundice, 14. 40-51.
- Ceelen's haemosiderosis:** 17. 25-48, 19. 256-7.
- Cerebral anaemia:** 16. 193-6.
— **congestion:** 16. 196.
— **symptoms:** in temporal arteritis, 15. 50; in kernicterus, 19. 132-6; in toxoplasmosis, 19. 59-60; in vitamin B₁ deficiency, 19. 334-6; in liver failure, 20. 421-3.
- Cerium:** in industrial toxicology, 12. 187.
- Changi camp:** 19. 330-7.
- Cheddite:** 12. 219.
- Chest expansion:** in ankylosing spondylitis, 18. 222; in smokers, 20. 143-4.
— **pain:** and massive dilatation of the left auricle, 18. 83-6; in pulmonary tuberculosis, 20. 318, 329.
— **volume:** in emphysema, 20. 254-7.
- Chinlofon:** 15. 6-7.
- Chloride metabolism:** in hunger oedema, 16. 14-16.
- Chlorides, excretion of:** in patients with heart failure, 19. 221-37; effect of smoking on, 18. 52.
- Chlorinated hydrocarbons:** in industrial toxicology, 12. 237-50.
— **naphthalene poisoning:** in industry, 12. 248-50.
- Chloroma:** aetiology of, and the nature of the green pigment, 15. 299-312.
- Cholaemia:** 20. 422, 425.
- Cholesterol:** 16. 25, 17. 16, 19. 174-8, 265.
- Choline:** 14. 39-40.
- Cholinesterase activity:** in myasthenia gravis, 13. 1-3, 20. 13-31.
- Chromium poisoning:** in industry, 12. 186-7.
- Chronic agranulocytosis:** experimental observations on, 17. 165-74; five cases of, 18. 173-85.
— **haemolytic anaemia.** *See* Anaemia.
— **intermittent juvenile jaundice:** 16. 83-98.
— **jaundice:** 17. 81.
— **liver disease:** ascites in, 16. 263-74; tests in, 19. 270-2.
— **monocytic leukaemia:** 20. 131-9.
— **porphyria:** associated with recurrent jaundice, 17. 123-37.
— **valvular disease:** from trauma, 13. 162-3; and bacterial endocarditis, 20. 96-101.
- Circulatory changes:** from haemorrhage, 11. 90-91; in oliguria of heart failure, 19. 215-19; in acute nephritis, 20. 168-9.
— **dynamics:** in emphysema, 18. 263-73.
- Cirrhosis of the liver:** 16. 226, 233-4, 19. 271-2; and hepatic coma, 20. 422-3, 425, 428-9; infective hepatitis and, 20. 403-19. *See also* Biliary cirrhosis.
- Coagulation time:** in haemophilia, 20. 301-4, 308.
- Cold antibodies:** 20. 275-92.
- Cold pressor response:** mechanism and significance of, 20. 261-73.
- Colitis, ulcerative:** potassium deficiency in, 20. 221-32.

- Coma, hepatic:** observations on the symptomatology and pathogenesis of, 20. 421-38.
- Congenital afibrinogenaemia:** 14. 101-11.
- **agenesis of a lung, complete,** 15. 125-39.
- **heart disease:** genetic and environmental factors in, 18. 379-91.
- **hypofibrinogenaemia:** 14. 106-9.
- **toxoplasmosis:** 19. 57-66.
- Congestion, cerebral:** 16. 196.
- Congestive cardiac failure:** influence of intravenous digoxin on renal function in, 20. 389-401.
- Constrictive pericarditis:** aetiology of, 17. 291-321.
- Coproporphyrin, urinary:** in liver disease, 19. 266-7; in porphyria, 17. 123-36.
- Coronary flow:** reduction in by pituitary (posterior lobe) extract in relation to the action of nicotine and to smoking, 18. 73-80.
- **thrombosis:** from trauma, 13. 153-7, 164.
- Costal cartilage:** calcification in emphysema, 20. 258.
- Cranial changes in dystrophia myotonica,** 19. 311.
- Craniofacial dysostosis:** the significance of ocular hypertelorism, 15. 171-81.
- Craniofacial dysostosis:** 15. 172.
- Cryptogenic acquired haemolytic anaemias:** 16. 245-62.
- Cushing's syndrome:** 14. 166; and thymic carcinoma, 18. 133-47.
- Cutaneous pigmentation:** in Albright's disease, 11. 149.
- Cyanosis:** with haemorrhagic telangiectasia, 19. 239-48.
- Cysteine:** 14. 39-51, 20. 210.
- Cysticercosis (*Taenia solium*):** 13. 107-21.
- Cystinuria:** aminoacid metabolism in, 20. 205-19.
- Cysts:** pituitary, 18. 330-1, 374-6; pulmonary, 18. 1-18, 20. 254.
- Dermatitis, arsenical:** treatment of, with dimercaptopropanol, 17. 49-79.
- **seborrhoeic:** and penicillin, 14. 184, 186-91.
- Dextrocardia:** 18. 379-80.
- DFP = Di-isopropylfluorophosphate, q.v.**
- Diabetes:** 15. 243-5.
- **blood-pressure in,** 20. 336-7.
- **pregnancy and:** 11. 45-75; toxæmia of, 11. 51-52; abnormal features of, 11. 51; hydramnios, 11. 53; influence of time of delivery on results, 11. 54; advisability of pregnancy in, 11. 56; breast-feeding, 11. 56; hypoglycaemia, 11. 59; methods of delivery and management of the baby, 11. 60-61.
- Diabetes, renal:** 15. 247-51.
- **insipidus:** 18. 7-10.
- **mellitus:** heredity of hypertension in, 20. 335-51.
- Diabetic glomerulosclerosis:** 19. 43-45, 20. 337.
- Diaphragm:** in emphysema, 20. 253-4, 257; in pulmonary infarction, 20. 239-40.
- Diaphragmatic hernia:** 11. 105-20.
- Diarrhoea:** and hepatitis, 14. 142.
- Dichlorodifluoromethane:** 12. 240.
- Dienoestrol:** 19. 75-88.
- Diet:** and loss of weight in obese patients, 13. 27-36.
- Dietary deficiency:** and hepatitis, 20. 413, 416; and megaloblastic anaemia of pregnancy, 20. 194; and post-menopausal osteoporosis, 19. 68; and Wernicke's encephalopathy, 19. 330-1.
- Diethylene dioxide poisoning:** in industry, 12. 251-2.
- Digoxin, intravenous:** action of in man, 13. 123-35; influence on renal function in congestive cardiac failure, 20. 389-401.
- Di-isopropylfluorophosphate:** 20. 21-30.
- Dimercaptopropanol (BAL):** treatment of arsenical dermatitis with, 17. 49-79.
- Dimethylarsine poisoning:** in industry, 12. 205.
- Dimorphic erythropoiesis:** 13. 62-67.
- Dinitrobenzene poisoning:** in industry, 12. 219-21.
- Dinitrophenol poisoning:** in industry, 12. 225-7.
- Diodoquin:** 15. 7.
- Dioxan poisoning:** in industry, 12. 251.
- Disk, prolapsed intervertebral:** 16. 157-79.
- Dithiol:** 17. 50.
- Diuresis:** in heart failure, 19. 188-220, 221-36; in nephritis, 19. 165-72; 20. 163-8; *see also* Water diuresis.
- Duodenal ulcer:** 18. 239-60, 19. 111-28.
- Dye tests:** in liver disease, 19. 263-4.
- Dyschondroplasia:** with haemangiomas (Maffucci's syndrome), 11. 203-28.
- Dysentery:** 15. 6-7.
- Dysenteric:** and hepatitis, 14. 142.
- **amoebic:** 15. 1-23.
- Dysphagia:** and massive dilatation of the left auricle, 18. 82-3.
- Dysplasia of bone:** fibrous, 11. 121-54.
- Dystrophia myotonica:** an endocrine study, 19. 303-18.
- Ears:** in blast injury, 12. 174-5.
- Echis carinata:** snake-bite by, 16. 291-303.
- Ecthyma:** 14. 184, 186-91.
- Ehrlich's test for urobilinogen:** 19. 272, 274.
- Eichhorn.** *See* Rappaport.

- Electrocardiogram**: in hypertension, 20. 1-12; after large doses of calciferol, 17. 213; in potassium deficiency, 20. 230.
- Electroencephalogram**: and fainting, 16. 204-6.
- Elliptocytosis in man**: associated with hereditary haemorrhagic telangiectasia, 12. 157-67.
- Embolitic nephritis**: focal, 17. 189-90.
- Embolism**: pulmonary, 20. 233-4; in subacute bacterial endocarditis, 20. 176-9.
- Emetine**: 15. 2-6, 14.
- **bismuth iodide**: 14. 3-6.
- Emotion**: and loss of consciousness, 16. 199-203.
- Emphysema**: circulatory dynamics in, 18. 263-73; and asthma, effect of ephedrine in, 19. 319-26; correlation between the radiological appearances and the clinical and spirometric state in, 20. 247-60.
- Encephalitic Parkinsonism**: 15. 155-70.
- Encephalopathy, Wernicke's**: 19. 327-38.
- Endocarditis, pneumococcal**: 12. 61-75.
- **subacute bacterial**: 20. 93-130.
- Endocrine features of Albright's disease**, 11. 146-9; influence in pernicious anaemia of pregnancy, 13. 99-100, 20. 200; imbalance and post-menopausal osteoporosis, 19. 68-70; study of dystrophia myotonica, 19. 303-18; *see also* **Cushing's syndrome**; **Hypopituitarism**.
- Enteric fever**: 15. 197.
- Environmental factors**: in congenital heart disease, genetic and, 18. 379-91.
- Eosinophilosis, pulmonary**: 17. 257-69.
- Eperythrozoa**, 14. 95-96.
- Ephedrine**: in asthma and emphysema, effect of, 19. 319-26.
- Epidemiology**: of the 1945 outbreak of poliomyelitis in Mauritius, 15. 183-208; of infective hepatitis in some units of the British army in Sicily and Great Britain, 1943-4: 14. 125-46.
- Epilepsy**: 16. 187-90.
- Epiphyseal growth**: in acute leukaemia, 19. 341.
- Epituberculosis**: 18. 21-28, 35-37.
- Erosion of the spine**: and massive dilatation of the left auricle, 18. 83.
- Erythrocyte fragility**: in acholuric jaundice, 12. 101-18; in steatorrhoea, 17. 14.
- **sedimentation**: in ankylosing spondylitis, 18. 223; and salicylate therapy, 17. 146-49, 19. 5, 16.
- Erythrocytic inclusions**: after splenectomy, anaemia associated with unidentified, 14. 75-100.
- **stippling** in lead poisoning, 18. 57-72.
- Erythropoiesis**: effect of liver therapy on: in pernicious anaemia, 11. 19-27; in megaloblastic anaemia of pregnancy, 13. 92-94; 20. 195-200.
- **dimorphic**, 13. 62-67.
- **megaloblastic**, 13. 54-62; 20. 192.
- Ethylene chlorhydrin poisoning**: in industry, 12. 250-1.
- Ethylene dichloride poisoning**: in industry, 12. 243-4.
- Evelyn**. *See* Malloy.
- Excretion of chlorides**: in patients with heart failure, 19. 221-37.
- Exophthalmic goitre**: and nodular goitre, hereditary and familial aspects of, 14. 207-19.
- Extracellular fluid**: in hunger oedema, 16. 12-13; in salicylate therapy, 19. 13.
- Extrasystolic arrhythmia**: from trauma, 13. 160-1.
- Eyebrows**: 18. 344, 19. 310-11.
- Facies**: in hypopituitarism, 18. 345-6.
- Faecal fat**: 15. 141-55.
- **mepacrine**: 16. 72.
- **salicylate**: 19. 6-7.
- Faeces**: in infective hepatitis, 12. 144.
- Fainting and flying**: 16. 181-209.
- Falciparum malaria**: mepacrine and, 16. 61-82.
- Familial aspects of exophthalmic goitre and nodular goitre**, 14. 207-19.
- **haemolytic anaemia**. *See* **Acholuric jaundice**.
- Fanconi syndrome**: mechanism of the, 16. 275-90.
- Fast-arginine**: 20. 208, 216.
- Fat**: in fibrositis of the back, 13. 40-3.
- **absorption**: in tropical sprue, 16. 99-109.
- **herniation**: in fibrositis of the back, 13. 43-49.
- **intestinal absorption of**, anomalies of: 1. Faecal fat, 15. 141-55; 2. Haematology of idiopathic steatorrhoea, 17. 9-24. — **metabolism**: in liver disease, 19. 265.
- Felty's syndrome**: treated by splenectomy, 20. 57-73.
- Fever**: in ankylosing spondylitis, 18. 218; in infective hepatitis, 12. 141, 16. 217; in subacute bacterial endocarditis, 20. 105.
- **rheumatic**: does sodium salicylate cure? 17. 139-51; and the Schönlein-Henoch syndrome, 17. 107.
- Fibrositis**: 13. 37-51, 14. 164, 16. 169-70.
- Fibrous dysplasia**: of bone, 11. 121-54.
- Filtration fraction**: in heart failure, 19. 194-9, 212-13.
- Fluid balance**: in azotaemia, 11. 98; in nephritis, 19. 165, 175.
- Flying**: fainting and, 16. 181-209.
- Foetal abnormalities**: and diabetes, 11. 53.
- Folic acid**: 20. 195-200.
- **antagonists**: bone and joint lesions in acute leukaemia and their response to, 19. 339-52.
- Follicle-stimulating hormone**: in dystrophia myotonica, 19. 312-13.
- Fractures**: in osteoporosis, 14. 157, 166.

- Freon:** 12. 240.
- Fulminating hepatitis:** acute, 16. 223-4, 20. 405-6, 414.
- Furunculosis:** 14. 186-91.
- Galactose tolerance tests:** in liver disease, 19. 264, 273-5; in thyrotoxicosis, 12. 129-39.
- Gall-bladder:** in hepatitis, 16. 226.
- Gallium poisoning:** in industry, 12. 187.
- Gastric acidity:** in idiopathic steatorrhoea, 17. 16.
- **hyperacidity:** treatment of by radium, with special reference to duodenal ulceration, 19. 111-28.
- **mucosa:** after irradiation, 19. 122-4.
- **secretory activity:** carbohydrate metabolism and, 18. 235-61.
- Gastritis, polypoid:** polyps of the stomach and, 12. 1-60.
- Gastro-duodenal haemorrhage:** azotaemia in, 11. 77-104.
- Gastro-intestinal tract:** in hepatitis, 16. 227.
- Genetic and environmental factors:** in congenital heart disease, 18. 379-91.
- **aspects:** of adrenocortical hyperplasia, 18. 142.
- **linkage:** in man, 14. 27-33.
- Genital tract:** in hypopituitarism, 18. 335-6.
- Glomerular filtration:** in heart failure, 19. 210-11, 225-7, 20. 155, 392-6.
- Glomerulosclerosis:** diabetic, 19. 43-45, 20. 337.
- Glucose, and gastric activity:** 18. 236-44, 255-6.
- **tolerance tests:** in glycogen disease, 15. 291; in hypopituitarism, 18. 349; in dystrophia myotonica, 19. 314.
- Glutamic acid:** 20. 435-6.
- Glycogen disease:** 15. 285-98.
- **formation:** in liver disease, 19. 264.
- Glycol group:** in industrial toxicology, 12. 250-2.
- Glycosuria:** classification of cases of, 15. 243-53.
- Goitre: exophthalmic and nodular:** hereditary and familial aspects of, 14. 207-19, 20. 293-7.
- **toxic, localized pretibial myxoedema** in association with, 11. 229-40.
- **toxic nodular:** 20. 293-7, 366.
- Gonadal function:** in dystrophia myotonica, 19. 311-12; in hypopituitarism, 18. 343, 350.
- Gonads:** in hypopituitarism, 18. 335-6; in dystrophic myotonica, 19. 312.
- Grahamella,** 14. 95.
- Granuloma:** of anterior pituitary, 18. 328, 370-3.
- Green pigment:** of chloroma, 15. 307-9.
- Gynaecomastia:** in Albright's disease, 11. 149; in dystrophia myotonica, 19. 312.
- Haemangiomata:** dyschondroplasia with (Maffucci's syndrome), 11. 203-28.
- Haemarthrosis:** in haemophilia, 20. 303, 307.
- Haematemesis:** and azotaemia, 11. 78-85; in oesophageal ulcer, 11. 114.
- Haematocrit:** in heart failure, 19. 195-205; in Type 1 nephritis, 19. 167, 20. 164-6.
- Haematological changes:** in nephritis, 19. 161-86.
- Haematology:** of idiopathic steatorrhoea, 17. 9-24; in ankylosing spondylitis, 18. 223; in Felty's syndrome, 20. 65-67; in pulmonary eosinophilosis, 17. 261-2, 265-6. *See Anaemia; Blood; Leukaemia.*
- Haemobartonella:** 14. 95.
- Haemochromatosis:** 17. 247-56.
- Haemodilution and -concentration:** in heart failure, 19. 189-99; in nephritis, 19. 167-9, 181-2.
- Haemoglobinuria:** chronic haemolytic anaemia with, 16. 258-9, 17. 1-8, 18. 105-121, 20. 275-92.
- **nocturnal:** 20. 288.
- **pamaquin:** 15. 25-46.
- **syphilitic cold:** 20. 288.
- Haemolysis:** in pernicious anaemia of pregnancy, 13. 101; with Raynaud's phenomena, 20. 285, 287.
- Haemolytic anaemia.** *See Anaemia.*
- **spherocytic jaundice:** acquired, 16. 257-8.
- Haemophilia:** in the human female, 20. 299-312.
- Haemorrhage:** gastro-duodenal, azotaemia in, 11. 77-104.
- Haemorrhagic phenomena:** in hepatitis, 16. 217, 227-8; caused by salicylates, 17. 156; 19. 4-5.
- **telangiectasia:** hereditary, with elliptocytosis, 12. 157-67.
- Haemosiderosis: idiopathic pulmonary,** 17. 25-48.
- **pulmonary changes** due to cardiac disease, with special reference to, 19. 249-62.
- Hair:** hypopituitarism and, 18. 343-4.
- **growth:** in dystrophia myotonica, 19. 310-11.
- Hashimoto's thyroiditis:** 20. 367.
- Hay fever:** treatment with antihistamine drugs, 17. 286.
- Headache:** in temporal arteritis, 15. 49-50.
- Heart:** in anaemia, 15. 107-24; congenital defects, 18. 380-1; effects of trauma, direct and indirect, on the, 13. 137-67; in hypopituitarism, 18. 336; non-penetrating injuries of the, 13. 139-44; penetrating wounds of the, 13. 138-9.
- **block** from trauma, 13. 160.
- **disease:** congenital, 18. 379-91; underlying, in subacute bacterial endocarditis, 20. 96-101; and pulmonary infarction, 20. 237, 239.

- Heart failure:** origin of oedema in, 19. 187-220; excretion of chlorides in patients with, 19. 221-37; in subacute bacterial endocarditis, 20. 119-23; uraemia complicating low salt treatment of, 20. 149-62; in acute nephritis, 20. 163-71.
- Hepatic coma:** observations on the symptomatology and pathogenesis of, 20. 421-38.
- **fibrosis.** See **Cirrhosis.**
 - **function:** in the oedematous syndrome, 16. 25. See also **Liver function.**
- Hepatitis,** 20. 424.
- **acute:** 16. 223-5; 19. 268-71.
 - **infective,** 12. 139-55; epidemiology of, 14. 125-46; and cirrhosis of the liver, 20. 403-19; outbreak in Burma of severe, 16. 211-36.
 - **subacute:** 16. 225.
- Hereditary aspects of exophthalmic and nodular goitre,** 14. 207-19, 20. 293-7.
- **haemorrhagic telangiectasia:** with cyanosis, 19. 239-48; elliptocytosis in man associated with, 12. 157-67.
- Heredity:** in hypertension, 16. 111-33; of hypertension in diabetes mellitus, 20. 335-51; in neurofibromatosis, 18. 101.
- Hernia, diaphragmatic:** and short oesophagus, 11. 105-20.
- Heterotopic calcification:** 14. 158.
- Hilar movement:** in emphysema, 20. 254.
- Histamine:** in infective hepatitis, 12. 144; and anaphylaxis, 17. 271-4; antihistamine drugs, 17. 271-90.
- **tests:** in gastric hyperacidity, 19. 113-19.
- Hoarseness:** and massive dilatation of the left auricle, 18. 83.
- Honeycomb lungs:** 18. 1-20.
- Hunger oedema:** 16. 1-19.
- Hydramnios:** in diabetic pregnancy, 11. 53.
- Hydrocarbons, chlorinated:** in industrial toxicology, 12. 237-50.
- Hydrochloric acid:** intraduodenal, and hypoglycaemia, 18. 238-9.
- Hydrogen arsenide poisoning:** in industry, 12. 203-5.
- Hydronephrosis:** 17. 91-92, 19. 42.
- Hyperacidity.** See **Gastric hyperacidity.**
- Hyperchloraemia and low plasma-bicarbonate, nephrocalcinosis associated with,** 14. 113-23, 19. 277-83.
- Hyperchloraemic renal acidosis of infants:** idiopathic, 19. 285-301.
- Hypercholesterolaemia:** 16. 25.
- Hyperparathyroidism:** 14. 166.
- Hyperplasia:** of the islets of Langerhans, 19. 21-31.
- **of the liver:** nodular, 16. 225-6.
- Hyperpnoea:** from salicylates, 17. 156, 158-61.
- Hypersplenism:** 20. 66-70.
- Hypertelorism:** ocular, 15. 171-81.
- Hypertension:** and flying, 16. 196; heredity in, 16. 111-33, 20. 335-51; and unilateral kidney disease, 16. 143-55; relation of to periarteritis nodosa, 17. 200; retinal vessels in, 18. 203-15; renal disease in, 19. 38-41, 53-54; electrocardiogram in, 20. 1-12.
- **benign:** renal function and prognosis in, 14. 171-82.
 - **severe:** in young persons, 17. 83-93.
- Hyperthyroidism:** and osteoporosis, 14. 157.
- Hypoalbuminaemia:** 16. 25.
- Hypofibrinogenaemia, congenital:** 14. 106-9.
- Hypoglycaemia:** pregnant diabetics and, 11. 59; and flying, 16. 197-8; and hydrochloric acid, 18. 238-9.
- **fatal:** pathological changes in the brain in, 11. 181-201.
 - **spontaneous:** 19. 21-31.
- Hypophysectomy:** 18. 330.
- Hypopituitarism:** syndrome of, 18. 319-78; with osteoporosis, 14. 157.
- Hypoplastic kidney:** 17. 92-93, 19. 45-46.
- Hypoproteinaemia:** in nephritis, 16. 25, 19. 178, 182.
- Hypothalamus:** 18. 319, 320, 337, 19. 139-40.
- Icterus gravis neonatorum:** in Albright's disease, 11. 150; see also **Kernicterus.**
- Idiopathic hyperchloraemic renal acidosis of infants (Nephrocalcinosis infantum):** 19. 285-301.
- **hypoplastic anaemia:** 13. 66-67.
 - **Parkinsonism:** 15. 155-70.
 - **pulmonary haemosiderosis:** 17. 25-48.
 - **steatorrhoea:** and absorption of intestinal fat, 15. 148; haematology of, 17. 9-24.
 - **thrombocytopenic purpura:** 18. 279-97.
- Impetiginized seborrhoea:** and seborrhoeic dermatitis, 14. 184, 186-91.
- Impetigo, annular:** 14. 184, 186-91.
- **sigilliform:** 14. 184, 186-91.
- Indeterminate Parkinsonism:** 15. 155-70.
- Indium:** in industrial toxicology, 12. 187.
- Indurite:** 12. 219.
- Industrial toxicology,** 12. 185-258; and see **Poisoning.**
- Infants:** idiopathic hyperchloraemic renal acidosis of, 19. 285-301.
- Infarction, pulmonary:** radiological study of, 20. 233-45.
- Infectious diseases:** pathogenesis of purpura in, 18. 310-15.
- Infective conditions of the skin:** therapeutic trial of penicillin in, 14. 183-96.
- **hepatitis:** epidemic, in Palestine, 12.

- 139-55; epidemiology of: 14. 125-46; and cirrhosis of the liver, 20. 403-19; severe outbreak of in Burma, 16. 211-36.
- Insulin**: and antihistamine drugs, 17. 285; and gastric activity: 18. 235-6, 244-7; and spontaneous hypoglycaemia, 19. 22.
- **tolerance**: in hypopituitarism, 18. 349; in dystrophia myotonica, 19. 314.
- Intracapsular glomerulosclerosis**: 19. 43-45, 20. 337.
- Intermittent juvenile jaundice**: chronic, 16. 83-98.
- Internment camp**: oedema in, 16. 47-60.
- Intervertebral disk**: prolapsed, 16. 157-79.
- Intestinal absorption of fat**, anomalies of: 1. Faecal fat, 15. 141-55; 2. Haematology of idiopathic steatorrhoea, 17. 9-24.
- Intracellular water**: in salicylate therapy, 19. 14.
- Intravenous digoxin**: action of in man, 13. 123-35; influence on renal function in congestive cardiac failure, 20. 389-401.
- Intrinsic factor deficiency**: in pernicious anaemia of pregnancy, 13. 98-99.
- Inulin clearance**. *See* **Glomerular filtration**.
- Iodine**: during X-ray therapy in thyrotoxicosis, 11. 4.
- **radioactive**, use of in the assessment of thyroid function, 20. 353-87.
- Iodine-oxyquinoline compounds**: in amoebiasis, 15. 6-8.
- Ischial tuberosities**: in ankylosing spondylitis, 18. 219.
- Islets of Langerhans**: 19. 25, 29-30.
- Jakob-Creutzfeldt syndrome**: 15. 163.
- Jaundice**: in Albright's disease, 11. 150; in hepatitis, 16. 216, 19. 273-4, 20. 403-19, 421-2, 425; van den Bergh reaction, 16. 135-42.
- **acholuric**: (familial haemolytic anaemia), with particular reference to changes in fragility produced by splenectomy, 12. 101-18; pathogenesis of, 12. 112-16; and cold agglutinins, 20. 288.
- **acquired haemolytic spherocytic**: 16. 257-8.
- **chronic**: 17. 81.
- **chronic intermittent juvenile**: 16. 83-98.
- **infantile**: 19. 129-49.
- **post-arsphenamine**: treatment of, with sulphur-containing aminoacids, 14. 35-56.
- **recurrent**: chronic porphyria associated with, 17. 123-37.
- *See also* **Hepatitis**.
- Juvenile jaundice**: chronic intermittent, 16. 83-98.
- Keratoconjunctivitis sicca**: 20. 33-42.
- Kernicterus**: 19. 129-46.
- Ketosis**: 11. 50.
- Kidney**: in hepatitis, 16. 227; in hypopituitarism, 18. 336; in periarteritis nodosa, 17. 175-202, 19. 41-42; *see also* **Renal disease**; **Nephritis**.
- **hypoplastic**: 17. 92-93, 19. 45.
- **unilateral kidney disease**: hypertension and, 16. 143-55.
- Kümmell's disease**: 14. 166.
- Kurchi bark**: 15. 9-10.
- Kyphosis**: in emphysema, 20. 254.
- **senile**: 14. 166.
- Langerhans, islets of**: 19. 25, 29-30.
- Lead content of the blood and its relation to rarefying processes in bone**, 15. 77-90.
- **poisoning**: in industry, 12. 187-200; stippling in, with reference to the effect of splenectomy, 18. 57-71.
- Lederer's anaemia**: 16. 255-6.
- Leukaemia**: blood lead in, 15. 84, 86; and chloroma, 15. 299-306.
- **acute**: bone and joint lesions in, and their response to folic acid antagonists, 19. 339-52.
- **chronic monocytic**: 20. 131-9.
- Linkage, genetic**: in man, 14. 27-33.
- Liver**: in methyl chloride poisoning, 11. 37; in hepatitis, 12. 152, 16. 216, 222, 223, 233, 20. 403-19; in hypopituitarism, 18. 336.
- **biopsy**: in diagnosis of haemochromatosis, 17. 247-56.
- **cirrhosis of the**. *See* **Cirrhosis**.
- **disease**: ascites in chronic, 16. 263-4; changes in liver function during, 19. 263-76.
- **extract**: in tropical sprue, 16. 103-5; in megaloblastic anaemia of pregnancy, 13. 92-4; 20. 195-200; in pernicious anaemia, 11. 19-26.
- **failure**, 20. 422.
- **fibrosis of**: 16. 226, 232-4; *and see* **Cirrhosis**.
- **function**: in cryptogenic acquired haemolytic anaemias, 16. 248-54; changes in, during liver disease, 19. 263-76, 20. 410-12.
- **massive necrosis of the**: acute, 20. 406; subacute, 20. 407.
- **proteolysed**: in the treatment of refractory anaemias, 13. 53-73.
- **pulp**: raw, 20. 196, 200.
- **sensitivity**: during use of antihistamine drugs, 17. 284-5.
- **therapy**: effect of, on erythropoiesis, 11. 19-27, 13. 92-94, 20. 195-200.
- Lobar pneumonia**: 11. 157-77, 20. 242.
- Looser's nodes**: in osteomalacia, 16. 33-45.
- Loss of weight**: in obese patients, 13. 27-36.
- Low salt treatment of heart failure**: uraemia complicating, 20. 149-62.
- Lumbo-dorsal sympathectomy**: 20. 7-9.

- Lung**: complete congenital agenesis of a, 15. 125-39; 'frozen', 20. 322, 329; infarction, 20. 233-45.
- **translucency**: in emphysema, 20. 250.
- **volume**: effect of tobacco on, 20. 141-7; effect of ephedrine on, 19. 319-25; in emphysema, 20. 249-50.
- Lungs**: essential brown induration of, 17. 25-48; haemosiderosis from cardiac disease, 19. 249-62; telangiectasis of the, 19. 239-48.
- **honeyscomb**: 18. 1-20.
- Lupus erythematosus**: 19. 47.
- Lymphoid tissue**: in hypopituitarism, 18. 337.
- Macrocytic anaemia**. *See* **Anaemia**.
- Macrocytosis**: in haemolytic anaemias, 16. 256-7.
- Maffucci's syndrome**: 11. 203-28.
- Malaria**: 14. 142, 15. 38, 16. 61-82.
- Malignant growths**: spinal, 14. 164. *See* **Carcinoma**.
- **hypertension**: 19. 38-40.
- Malloy and Evelyn method**: in van den Bergh reaction, 16. 139-40.
- Malta**: poliomyelitis epidemic in, 14. 1-26.
- Mammary glands**: in hypopituitarism, 18. 337.
- Marchiafava-Micheli syndrome**: 16. 258, 17. 1-8, 18. 105-21.
- Marrow**. *See* **Bone-marrow**.
- **hyperplasia**: and blood lead, 15. 83.
- Massive dilatation of the left auricle**, 18. 81-91.
- Maternal rubella**: 18. 381-2, 386-7, 389.
- Mauritius**: epidemiology of the 1945 outbreak of poliomyelitis in, 15. 183-208.
- Measles**: pneumonia secondary to, 11. 175.
- Megakaryocytes**: 18. 288-93, 306-7.
- Megaloblastic anaemia**. *See* **Anaemia**.
- Melaena**: in oesophageal ulcer, 11. 114.
- Mélinite**: 12. 225.
- Melorheostosis**: associated with tuberosesclerosis, 12. 77-100.
- Mendelian inheritance**: 14. 27-33, 16. 111-18, 18. 101-2, 379-80, 20. 293-7, 303, 309-10, 335-6, 347.
- Mepacrine**: and haemoglobinuria, 15. 37, 42-43; and falciparum malaria, 16. 61-82; and hepatitis, 16. 230.
- Mercury poisoning**: in industry, 12. 205-6; metallic, 12. 206-9; organic compounds of, 12. 209-11.
- Metabolism**: in gastro-duodenal haemorrhage, 11. 83-84; aminoacid, in cystinuria, 20. 205-19; chloride, in hunger oedema, 16. 14-16; mineral, in osteoporosis, 14. 153-4, 163, 19. 69-84; protein and water, in salicylate therapy, 19. 10-15.
- Metals**: in industrial toxicology, 12. 186-211.
- Methionine**: 14. 39-51.
- Methyl chloride poisoning**: in industry, 11. 29-43, 12. 239-41.
- Migraine**: and antihistamine drugs, 17. 287.
- Mikulicz's syndrome**, 20. 33.
- Milkman's syndrome**. *See* **Osteomalacia**.
- Miscarriage**: 18. 388-9.
- Monocytic leukaemia**: chronic, 20. 131-9.
- Monothiol**: 17. 49.
- Multiple neurofibromatosis**: 18. 93-103.
- Muscarine effects of acetylcholine**: 16. 240-2.
- Muscle**. *See* **Blood and muscle**.
- Myasthenia gravis**: causation, 13. 1-18; acetylcholine and, 16. 237-43; cholinesterase activity of blood and muscle in, 20. 13-19; cholinesterase inhibition and signs and symptoms in, 20. 21-31.
- Myelomatosis, multiple**: 19. 47.
- Myocardium**: rupture of the, 13. 146-8; contusion of the, 13. 148-51.
- Myxoedema**: localized pretibial, in association with goitre, 11. 229-40; onset in relation to thyrotoxicosis, 11. 231; and radioactive iodine, 20. 367.
- Neoarphenamine**: action on liver, 14. 37-38; action on skin, 17. 67-78.
- Neostigmine**: 20. 22-28.
- Nephritis**: biochemical and haematological changes in Type 1 and Type 2, 19. 161-86; clinical and pathological study of, 18. 149-71; oedematous syndrome of, with special reference to prognosis, 16. 21-31; and Schönlein-Henoch syndrome, 17. 117.
- **acute**: heart failure in, 20. 163-71.
- **diffuse glomerular**: 17. 190-1, 18. 150-5.
- **focal embolic**: 17. 189-90.
- Nephrocalcinosis**: associated with hyperchloraemia and low plasma-bicarbonate, 14. 113-23, 19. 277-83.
- **infantum**: 19. 285-301.
- Nervous signs**: in airmen, 16. 185-91; in Albright's disease, 11. 150; in blast injury, 12. 180; in hepatitis, 16. 217-19; in kernicterus, 19. 132-63; in polyarteritis nodosa, 15. 272-5; in hepatic coma, 20. 421-7.
- **system**: in methyl chloride poisoning, 11. 37.
- Neuritis, peripheral**: association of bronchial carcinoma and, 19. 97-109.
- Neurofibromatosis**: of sympathetic ganglia, 17. 89-90.
- **multiple**: 18. 93-103.
- Neurological sequelae**: of Rh sensitization, 19. 129-49.
- Neurosyphilis**: and Parkinsonism, 15. 163-5.
- Neutrophil leucopenia**: 16. 254, 17. 165-73, 18. 173-85, 20. 66.

- Nickel**: in industrial toxicology, 12. 187.
- Nicotine**: reduction in coronary flow by, 18. 73-80.
- **effects**: of acetylcholine, 16. 238-40.
- Nicotinic acid**: content of blood in health and disease, 14. 197-205; and tropical sprue, 16. 102-3.
- Nitrobenzene poisoning**: in industry, 12. 217-19.
- Nitrogen absorption**: in azotaemia, 11. 83.
- Nocturia**: 19. 189, 195-7, 214.
- Nodular goitre**: hereditary and familial aspects, 14. 207-19, 20. 293-7.
- **hyperplasia**: and severe hepatitis, 16. 225-6.
- Nutrition**: and hepatitis, 16. 230-2; hypopituitarism and, 18. 338-42.
- Nutritional deficiency**: in pernicious anaemia of pregnancy, 13. 97-98, 20. 194.
- **oedema**: in an internment camp, 16. 58.
- Obese patients**: loss of weight in, 13. 27-36.
- Ocular hypertelorism**: 15. 171-81.
- **manifestations**: of polyarteritis nodosa, 18. 123-32, 15. 272-5; of tuberoscclerosis, 15. 209-20.
- **symptoms**: in temporal arteritis, 15. 51-53.
- Oculomotor symptoms**: in temporal arteritis, 15. 51-53.
- Oedema**: effect of rest, &c., on, 16. 7-9; in an internment camp, 16. 47-60; in hepatitis, 16. 217; in nephritis, 19. 172, 181-2; in heart failure, 19. 187-220.
- **hunger**: 16. 1-19.
- Oedematous syndrome**: of nephritis, with special reference to prognosis, 16. 21-31.
- Oesophagus**: chronic peptic ulcer of the, 11. 105-20.
- Oestradiol**: 19. 72, 83-88, 91.
- Oestrogens**: in ankylosing spondylitis, 18. 230; treatment of postmenopausal osteoporosis with, 19. 67-96.
- Optic atrophy**: in von Recklinghausen's disease, 18. 93-103.
- Organic mercury compounds**: poisoning by, in industry, 12. 209-11.
- Osler, Sir William**: 18. 275-7, 403-4.
- Osteogenesis imperfecta**: 14. 166.
- Osteolytic lesions**: of acute leukaemia, 19. 340.
- Osteomalacia**: and osteoporosis, 14. 162-3; 19. 90; with Looser's nodes (Milkman's syndrome) due to a raised resistance to Vitamin D, 16. 33-45.
- Osteoporosis, postmenopausal**: clinical manifestations, and the treatment with oestrogens, 19. 67-96.
- **spinal**, of unknown origin, 14. 147-70.
- Oxycephaly**: 15. 171.
- Paget's disease**: 14. 166.
- Pamaquin haemoglobinuria**: 15. 25-46.
- Pancreas**: 18. 337, 19. 25.
- Pancreatitis**: and absorption of intestinal fat, 15. 150.
- Paralysis agitans**: 15. 155-70.
- Parathyroid function**: in dystrophia myotonica, 19. 315-16.
- Parathyroids**: 18. 337.
- Parkinsonian syndrome**: changes in, in the 20th century, 15. 155-70.
- Parkinsonism**: neurosyphilis and, 15. 163-5.
- **encephalitic**: 15. 155-70.
- **idiopathic**: 15. 155-70.
- **indeterminate**: 15. 155-70.
- Paroxysmal haemoglobinuria**: 16. 258-9, 17. 1-8, 18. 105-21, 20. 275-92.
- **tachycardia**, 13. 158-9.
- Pathogenesis** of hepatic coma, observations on the symptomatology and, 20. 421-38.
- Pathological changes in the brain** in fatal hypoglycaemia, 11. 181-201.
- Pathology of Sjögren's disease**: 20. 33-42.
- Penicillin**: in infective conditions of the skin, 14. 183-96; in ankylosing spondylitis, 18. 230; in bacterial endocarditis, 20. 102-3, 107-9; in staphylococcal pneumonia, 20. 52-53.
- Peptic ulcer**: of the oesophagus, chronic, 11. 105-20; radium treatment of, 19. 111-28.
- Periarthritis nodosa**: clinical features, 15. 59; kidney in, 17. 175-202, 19. 41-42; relation of hypertension to: 17. 200; and antihistamine drugs, 17. 287; *see also* Polyarteritis nodosa.
- Pericardectomy**: 17. 294-5, 311-14.
- Pericarditis, constrictive**: 17. 291-321.
- **tuberculous**: 17. 291-321.
- Pericardium**: non-penetrating injuries of the, 13. 144-6.
- Peripheral neuritis**: association of bronchial carcinoma and, 19. 97-109.
- Periostitis**: leukaemic, 19. 340-1.
- Pernicious anaemia, Addisonian**, 11. 19-27, 13. 67, 68, 72; blood lead in, 15. 85-6; and polyps of the stomach, 12. 9-10; serum-iron in, 13. 22.
- **of pregnancy**, 13. 75-105, 20. 187-204.
- Pertussis**: pneumonia secondary to, 11. 177-9.
- Phenylenediamine poisoning**: in industry, 12. 232-3.
- Pheochromocytoma**: 19. 48.
- Phosphatase**: serum alkaline: in calciferol poisoning, 17. 222; in liver disease, 19. 266; in postmenopausal osteoporosis, 19. 72-82, 91.
- **prostatic**: estimation of in serum, and its use in the diagnosis of prostatic carcinoma, 15. 221-41.
- Phosphorus**: 14. 167.

- Phosphorus balances:** 19. 70-85.
- Pigment excretion:** in liver disease, 19. 263-75; in idiopathic steatorrhoea, 17. 16-17; in porphyria, 17. 123-36.
- Pituitary:** and Cushing's syndrome, 18. 144-5; honeycomb lungs in disorders of, 18. 7-10; lesions of the, 18. 320-32.
- (posterior lobe) extract: reduction in coronary flow by, 18. 73-80.
- Plagiocephaly:** 15. 171-2.
- Plasma:** acid-base changes, in salicylate therapy, 19. 7-9.
- albumin levels: in hunger oedema, 16. 3-4; in Type 2 nephritis, 19. 182.
- bicarbonate, low: nephrocalcinosis associated with hyperchloraemia and, 14. 113-23, 19. 277-83.
- bilirubin: 16. 89-90.
- chloride: in hunger oedema, 16. 15.
- diastase: in glycogen disease, 15. 293.
- iodide: and thyroid function, 20. 375-84.
- protein: in beri-beri, 15. 95; in heart failure, 19. 200-3; in hepatitis, 19. 264-5, 20. 411-12, 416; in hunger oedema, 16. 2, 4, 9-12; in oedematous syndrome, 16. 25; in Type 2 nephritis, 19. 177-8, 181-2; and pamaquin haemoglobinuria, 15. 31-33.
- salicylate. *See* Salicylate.
- volume: in hunger oedema, 16. 4-7; in nephritis, 19. 167-9, 181-2, 20. 168-70; in salicylate therapy, 19. 10.
- Platycephaly:** 15. 172.
- Pleural adhesions:** — effusion. *See* Artificial pneumothorax.
- Pleurisy:** in pulmonary infarction, 20. 239.
- Pneumococcal endocarditis:** 12. 61-75.
- Pneumococci:** in pneumonia (infants), 11. 160-6; (adults), 11. 167-74; in pneumonia secondary to measles and pertussis, 11. 175-9.
- Pneumonia:** in infants, children, and adults, 11. 155-80; secondary to measles, 11. 175-7; secondary to pertussis, 11. 177-9.
- lobar: 11. 167-74, 20. 242.
- primary staphylococcal: 20. 43-55.
- Pneumothorax:** artificial, 20. 313-34.
- Poisoning:** and flying, 16. 198.
- in industry: 12. 185-258; metals, 12. 186-211; aromatic compounds, 12. 212-37; chlorinated hydrocarbons, 12. 237-50; glycol group, 12. 250-2.
- methyl chloride: 11. 29-43.
- *See also* Lead poisoning.
- Pollomyelitis epidemica:** in Malta, 14. 1-26; in Mauritius, 15. 183-208.
- Polyarteritis nodosa:** clinical aspects of, 15. 255-83; in childhood, 15. 279; ocular manifestations of, 18. 123-32; and Schönlein-Henoch syndrome, 17. 117; and severe hypertension, 17. 90-91; *see also* Periarteritis nodosa.
- Polypoid gastritis:** 12. 31-60.
- Polyps:** of the stomach, 12. 1-31; and pernicious anaemia, 12. 9-10.
- Polyserositis:** 17. 317-21.
- Porphyria, chronic:** associated with recurrent jaundice, 17. 123-37.
- Porphyrin:** 17. 127-34.
- Post-arsphenamine jaundice:** treatment of, with sulphur-containing aminoacids, 14. 35-56.
- Postmenopausal osteoporosis:** clinical manifestations, and the treatment with oestrogens, 19. 67-96.
- Post-partum necrosis:** of pituitary, 18. 376-8.
- Potassium deficiency:** in Cushing's syndrome, 18. 140-1; in ulcerative colitis, 20. 221-32.
- and sodium balances: in salicylate therapy, 19. 14; in ulcerative colitis, 20. 223-4.
- Pregnancy:** and diabetes, 11. 45-75; pernicious anaemia of, 13. 75-105; and the puerperium, megaloblastic anaemia of, 20. 187-204.
- Pretibial myxoedema:** localized, in association with goitre, 11. 229-40.
- Primary optic atrophy:** in von Recklinghausen's disease (multiple neurofibromatosis), 18. 93-103.
- staphylococcal pneumonia: 20. 43-55.
- thyrotoxicosis, 11. 7, 14. 207-19.
- tuberculosis. *See* Tuberculosis.
- Prolapsed intervertebral disk:** aetiology, diagnosis, and treatment of, 16. 157-79.
- Prostatic carcinoma:** diagnosis of, 15. 221-41.
- phosphatase in serum: estimation of, and its use in the diagnosis of prostatic carcinoma, 15. 221-41.
- Protein, food:** in oedema in an internment camp, 16. 47-49.
- metabolism: in liver disease, 19. 264-5; in salicylate therapy, 19. 10-12.
- tissue: in haematemesis, 11. 88-93.
- *See also* Plasma-protein.
- Proteolysed liver:** in the treatment of refractory anaemias, 13. 53-73.
- Prothrombin consumption index:** of haemophilic plasma, 20. 301, 304-6.
- Pruritus:** effect of antihistamine drugs in, 17. 284.
- Pseudarthroses:** 14. 152.
- Psychogenic basis** of some so-called rheumatic pains, 14. 57-74.
- Pulmonary changes** due to cardiac disease, with special reference to haemosiderosis, 19. 249-62.
- eosinophilosis: 17. 257-69.
- haemosiderosis: idiopathic, 17. 25-48.

- Pulmonary hypoventilation**: post-operative, 20. 242.
- **infarction**: radiological study of, 20. 233-45.
- **tuberculosis**. *See* **Artificial pneumothorax**.
- Purpura**, allergic, and antihistamine drugs, 17. 286; occurring with infections, 18. 310-18.
- **anaphylactoid**: 17. 95-122.
- **senile**: 19. 151-9.
- **thrombocytopenic**, 18. 279-97, 299-318.
- Putrescine**: 20. 216.
- Pyelonephritis**: 19. 34-38, 20. 337-8.
- Pyrene**: 12. 242.
- Pyribenzamine**: 17. 280-7.
- Quinoxyl**: 15. 6-7.
- Rack-a-rock**: 12. 219.
- Radioactive iodine**: in the assessment of thyroid function, use of, 20. 353-87.
- Radiological appearances**: and the clinical and spirometric state in emphysema, 20. 247-60; in Albright's disease, 11. 135-40; in ankylosing spondylitis, 18. 188-92, 226-8; in artificial pneumothorax, 20. 318-19; in congenital toxoplasmosis, 19. 61; in dystrophia myotonica, 19. 311; in leukaemia, 19. 340-1; in oesophageal ulcer, 11. 114-18; in osteoporosis, 14. 151-2, 19. 86.
- **of the chest**: in blast injury, 12. 180; in emphysema, 20. 250-59; in haemosiderosis, 17. 34-39, 19. 250-1; in honeycomb lung, 18. 16; left auricular enlargement, 18. 86-88; left ventricular enlargement, 18. 207; staphylococcal pneumonia, 20. 49-60; telangiectasis, 19. 245.
- **study of pulmonary infarction**: 20. 233-45.
- Radium**: treatment of gastric hyperacidity by, with special reference to duodenal ulceration, 19. 111-28.
- Rappaport and Eichhorn method**: in van den Bergh reaction, 16. 138.
- Rarefying processes**: in bone, the lead content in blood and its relation to, 15. 77-90.
- Raw liver pulp**: 20. 196, 200.
- Raynaud's phenomena**, chronic haemolytic anaemia, and the formation of cold antibodies, association of, 20. 275-92.
- Refractory anaemias**: proteolysed liver in the treatment of, 13. 53-73.
- Renal acidosis**: of infants: idiopathic hyperchloraemic, 19. 285-301.
- **diabetes**: 15. 247-51.
- **disease**: clinical and pathological study of: 1. Nephritis, 18. 149-71; 2. Diseases other than nephritis, 19. 33-55.
- **elimination**: of chlorides, 19. 222, 226-31, 20. 151-4.
- Renal function**: in benign hypertension, 14. 171-82; in gastro-duodenal haemorrhage, 11. 82, 91-93; in heart failure, 19. 187-237; in renal acidosis of infants, 19. 285-301; in nephrocalcinosis, 14. 118-21; in salt depletion, 20. 149-61; in congestive cardiac failure, influence of intravenous digoxin on, 20. 389-401.
- **glycosuria**: 15. 246-7.
- **hypoplasia**: 19. 45-46.
- **plasma-flow**: in heart failure, 19. 205-18, 20. 392-6.
- Respiratory symptoms**: in blast injury, 12. 176; in ankylosing spondylitis, 18. 218; in salicylate therapy, 17. 156, 158-61, 19. 4.
- **system**: in polyarteritis nodosa, 15. 275-7.
- Reticulo-endothelial system**: diseases of, blood lead in, 15. 83-6; and monocytic leukaemia, 20. 136-8.
- Retinal vessels**: in hypertension, 18. 203-15.
- Rh sensitization**: neurological sequelae of, 19. 129-49.
- Rhenium**: in industrial toxicology, 12. 187.
- Rheumatic fever**: and Schönlein-Henoch syndrome, 17. 117; does sodium salicylate cure? 17. 139-51.
- **acute**: mode of action of salicylate in, 19. 1-19.
- **pains**: psychogenic basis of some so-called, 14. 57-74.
- Rheumatoid arthritis**: and ankylosing spondylitis, 18. 197, 225; and Felty's syndrome, 20. 57-73.
- Rhinitis, perennial**: treatment with antihistamine drugs, 17. 86-7.
- Rhythm**. *See* **Arrhythmia**.
- Rib-crowding**, apical: in emphysema, 20. 254.
- Riboflavine**: and tropical sprue, 16. 102-3.
- Rice**: and beri-beri, 15. 98-104.
- Rickets**: resistant, 16. 43.
- Right auricular pressure**: in heart failure, 19. 200; in acute nephritis, 20. 167.
- Roburite**: 12. 219.
- Rubella**: thrombocytopenic purpura occurring after, 18. 299-318; and heart disease, 18. 381-2, 386-7, 389.
- Salicylate**: emetic action of, 17. 157-8; excretion of, 17. 141-9, 239-42, 19. 6-7; hyperpnoeic action of, 17. 158-61; salicylate syndrome, 19. 4, 15.
- **plasma concentrations**: 17. 140-50, 154-7, 229-46, 19. 5-12; mode of action of, in acute rheumatic fever, 19. 1-19.
- **sodium**: inaccurate dosage, 17. 235; rectal administration, 17. 235-6; does it cure rheumatic fever? 17. 139-51.
- **therapy**, toxic manifestations of, 17. 153-63.

- Salivary glands:** in Sjögren's disease, 20. 33-34, 40.
- Salt deficiency:** in gastro-duodenal haemorrhage, 11. 89-90; with mercurial diuretics, 20. 149-61.
- Scaphocephaly:** 15. 171.
- Schönlein-Henoch syndrome** (anaphylactoid purpura): 17. 95-122.
- Sciatica:** review of 300 cases of, 16. 157-79; natural history of, 16. 171.
- Scleroderma:** and antihistamine drugs, 17. 287; and renal disease, 19. 48.
- Sclerosis, tuberosa:** melorheostosis associated with, 12. 77-100; ocular manifestations of, 15. 209-20; honeycomb lungs in, 18. 5-7.
- Scoliosis:** 16. 162-5.
- Scurvy:** 14. 157.
- Seborrhoea, impetiginized:** and penicillin, 14. 184, 186-91.
- Sella turcica:** changes in, 19. 311; empty, 18. 328, 373-4; tumours related to, 18. 330-2.
- Senile kyphosis:** 14. 166.
- **purpura:** 19. 151-9.
- Serum alkaline phosphatase.** *See* Phosphatase.
- **bilirubin:** 16. 135-42; in intermittent juvenile jaundice, 16. 89-90; and intestinal absorption of fat, 17. 16; in liver disease, 19. 263, 273-5; 20. 411, 416.
- **calcium,** after high dosage of calciferol, 17. 215-18.
- **iron:** in health and disease, 13. 19-26.
- **proteins:** in nephritis, 19. 169, 170, 178, 181-2; *see also* Plasma protein.
- **sickness:** and antihistamine drugs, 17. 284.
- Severe hypertension in young persons:** 17. 83-93.
- **infective hepatitis:** outbreak of in Burma, 16. 211-36.
- Sex function:** in hypopituitarism, 18. 343; in dystrophia myotonica, 19. 311-12.
- Sexual precocity:** in Albright's disease, 11. 147-8.
- Sigilliform impetigo:** 14. 184, 186-91.
- Sinus bradycardia:** from trauma, 13. 159-60.
- Sjögren's disease:** a contribution to the pathology of, 20. 33-42.
- Skeletal precocity:** in Albright's disease, 11. 146-7.
- **system:** in hypopituitarism, 18. 337.
- Skin:** in hypopituitarism, 18. 337, 344; therapeutic trial of penicillin in infective conditions of the, 14. 183-96; manifestations in polyarteritis nodosa, 15. 277-79.
- Skull, the:** in dystrophia myotonica, 19. 311.
- Smoking:** effect on water diuresis in man, 18. 51-5; effect on lung-volume, 20. 141-7; reduction in coronary flow by, 18. 73-80.
- Snake-bite by *Echis carinata*:** 16. 291-303.
- Sodium:** renal excretion, 19. 233-4; depletion, 20. 157; balance in ulcerative colitis, 20. 222-8.
- **benzoate:** detoxication tests in snake-bite, 16. 296-7.
- **salicylate.** *See* Salicylate.
- Spherocytic jaundice:** acquired haemolytic, 16. 257-8.
- Spinal osteoporosis:** of unknown origin, 14. 147-70.
- Spine,** erosion of, and massive dilatation of the left auricle, 18. 83.
- Spirometric state:** and radiological appearances, in emphysema, 20. 247-60.
- Spleen:** in Felty's syndrome, 20. 64-65; in hepatitis, 16. 226-7; in idiopathic thrombocytopenic purpura, 18. 295-6; in hypopituitarism, 18. 337.
- Splenectomy:** changes in fragility produced by, 12. 101-18; anaemia associated with unidentified erythrocytic inclusions after, 14. 75-100; Felty's syndrome treated by, 20. 57-73; in acquired haemolytic anaemia, 16. 254-5, 259, 20. 290; in chronic agranulocytosis, 18. 182; in idiopathic thrombocytopenic purpura, 18. 279-318; stippling in lead poisoning, with reference to the effect of, 18. 57-71.
- Spondylitis, ankylosing:** 14. 165, 18. 187-201, 217-34.
- Spondylolisthesis:** 14. 165.
- Spontaneous hypoglycaemia:** due to hyperplasia of the islets of Langerhans, treatment of, 19. 21-31.
- Sprue, tropical:** fat absorption in, 15. 149, 16. 99-109.
- Staphylococcal pneumonia:** primary, 20. 43-55.
- Steatorrhoea, idiopathic:** and intestinal absorption of fat, 15. 148; haematology of, 17. 9-24.
- Sternal marrow, sternal puncture.** *See* Bone-marrow.
- Stippling in lead poisoning:** with reference to the effect of splenectomy, 18. 57-71.
- Stomach:** polyps of the, and polypoid gastritis, 12. 1-60.
- Subacute bacterial endocarditis:** 20. 93-130.
- **hepatitis:** 16. 225.
- Sulphapyridine:** in primary pneumonia (infants), 11. 161; (adults), 11. 168; in pneumonia secondary to measles, 11. 175; in pneumonia secondary to pertussis, 11. 178.
- Sulphur-containing aminoacids:** treatment of post-arsphenamine jaundice with, 14. 35-56.
- Surgery:** in ankylosing spondylitis, 18. 230; in constrictive pericarditis, 17. 294, 311-14.

- Sympathetic ganglia:** neurofibromatosis of, 17. 89-90.
- Symptomatology** and pathogenesis of hepatic coma, 20. 421-38.
- Syndrome of hypopituitarism**, 18. 319-78.
— *See under proper names.*
- Syphilis:** and osteoporosis, 14. 156; and haemolytic anaemia, 20. 288.
- T 1824 disappearance curves:** in heart failure, 19. 195-9, 203.
- Taenia saginata:** 13. 108.
— **solium:** 13. 107-21.
- Tachycardia, paroxysmal:** from trauma, 13. 158-9.
- Tapeworm:** 13. 107-21.
- Teeth:** and spinal osteoporosis, 14. 157; and hypopituitarism, 18. 337.
- Telangiectasia:** hereditary haemorrhagic: with cyanosis, 19. 239-48; elliptocytosis in man associated with, 12. 157-67.
- Telangiectasis:** of the lungs, 19. 239-48.
- Temporal arteritis:** a generalized vascular disease, 15. 47-75.
- Testosterone:** 19. 77-78.
- Tetrachlorethane poisoning:** in industry, 12. 244-6.
- Tetrachloromethane poisoning:** in industry, 12. 241-3.
- Tetra-ethyl lead poisoning:** in industry, 12. 200-1.
- Tetramethylaniline (tetralite, tetryl) poisoning:** in industry, 12. 231.
- Thallium:** in industrial toxicology, 12. 187.
- Therapeutic trial of penicillin** in infective conditions of the skin, 14. 183-96.
- Thiamine.** *See* Vitamin B₁.
- Thiol:** 14. 37-39, 17. 49.
- Thoracic diameter:** in emphysema, 20. 255-8.
- Thoracoscopy:** 20. 319-20.
- Thromboangitis obliterans:** 15. 59.
- Thrombocytopenia:** in acute infections, 18. 309-10.
- Thrombocytopenic purpura:** idiopathic, 18. 279-97; occurring after rubella, 18. 299-318.
- Thrombosis, coronary:** from trauma, 13. 153-7, 164.
- Thymic carcinoma:** Cushing's syndrome and, 18. 133-47.
- Thymus:** in hypopituitarism, 18. 337.
- Thyroid enlargement:** in Albright's disease, 11. 148-9.
— **function:** in dystrophia myotonica, 19. 315; and radioactive iodine, 20. 353-87.
— **gland:** in hypopituitarism, 18. 335.
— **iodine:** uptake, 20. 369-73; clearance, 20. 375-6.
- Thyrototoxicosis:** 14. 207-19; X-ray therapy in, 11. 1-17; iodine and medical treatment during X-ray therapy, 11. 4; primary, 11. 7; pretibial myxoedema in relation to, 11. 231; secondary, 20. 293-7; diagnosis, 20. 355, 361-86.
— **galactose tolerance tests** in, 12. 129-39.
- Titanium:** in industrial toxicology, 12. 187.
- TNT:** 12. 221-5.
- Tobacco:** effect of, on lung-volume, 20. 141-7.
- Tonsil-adenoid operation:** in relation to the health of a group of school-girls, 12. 119-28.
- Toxaemia of pregnancy:** in diabetics, 11. 51.
- Toxic effects of calciferol:** 17. 203-28.
— **manifestations of sodium salicylate therapy**, 17. 153-63.
— **nodular goitre** (secondary thyrotoxicosis): hereditary and familial aspects of, 20. 293-7; assessment of, 20. 366-8.
- Toxicology.** *See* Poisoning.
- Toxoplasmosis:** congenital, 19. 57-66.
- Transfusions.** *See* Blood-transfusion.
- Trauma, direct and indirect:** effects of, on the heart, 13. 137-67.
- Trichlorethylene poisoning:** in industry, 12. 246-8.
- Trigonocephaly:** 15. 172.
- Trinitrotoluene poisoning:** in industry, 12. 221-5.
- Tri-ortho-cresyl phosphate poisoning:** in industry, 12. 233-7.
- Tropical sprue:** and absorption of fat, 15. 149, 16. 99-109.
- Tuberculosis:** and spinal osteoporosis, 14. 166.
— **primary:** bronchoscopic studies in, in childhood, 18. 21-49.
— **pulmonary.** *See* Artificial pneumothorax.
— **renal:** 19. 48.
- Tuberculous pericarditis:** 17. 291-321.
- Tuberosc sclerosis:** melorheostosis associated with, 12. 77-100; ocular manifestations of, 15. 209-20; honeycomb lungs in, 17. 5-7.
- Tubular reabsorption:** of bicarbonate, 19. 294-7; of chlorides, 19. 232-6; of water, 19. 218, 20. 392-8.
- Tumours:** pituitary, 18. 330-2, 374-6.
- Ulcer, peptic:** of the oesophagus, chronic, 11. 105-20.
- Ulceration:** duodenal, 19. 111-28.
- Ulcerative colitis:** potassium deficiency in, 20. 221-32.
- Unilateral kidney disease:** hypertension and, 16. 143-55.
- Uraemia:** complicating low salt treatment of heart failure, 20. 149-62. *See also* Blood-urea.
- Urea:** elimination of, after gastro-intestinal haemorrhage, 11. 91; in the van den Bergh reaction, 16. 138-9; *see also* Blood-urea.

- Urea clearance tests:** after high dosage of calciferol, 17. 214-15.
- Urinary free acid, ammonia, and phosphate in renal acidosis,** 19. 289.
- **aminoacids:** 20. 205-13; in hepatic coma, 20. 427-31.
- **bile pigments:** in liver disease, 19. 263, 267-74.
- **changes:** in hunger oedema, 16. 13-14; in heart failure, 19. 188-220.
- **coproporphyrin:** in liver disease, 19. 266-7; in chronic porphyria, 17. 127-33.
- **diastase:** in glycogen disease, 15. 293.
- **formic acid:** in methyl chloride poisoning, 11. 39.
- **iodine:** and thyroid function, 20. 373-5.
- **mepacrine:** 16. 71-77.
- **salicylate:** 17. 140-9, 239-42, 19. 6-7.
- Urine:** after haematemesis, 11. 81; in infective hepatitis, 12. 144; in ankylosing spondylitis, 18. 223; in postmenopausal osteoporosis, 19. 70; in renal acidosis, 19. 289-94.
- **chloride:** in hunger oedema, 16. 15; in heart failure, 19. 221-36.
- Urobilinogen:** Ehrlich's test for, 19. 274-5.
- Urticaria:** effect of antihistamine drugs in, 17. 283-4.
- Valvular disease:** chronic, from trauma, 13. 162-3.
- **lesions:** from trauma, 13. 161-2; in subacute bacterial endocarditis, 20. 96-101.
- van den Bergh reaction, the:** significance of, 16. 135-42. *See also* Serum-bilirubin.
- Venous pressure:** and digoxin, 20. 392-7; in acute nephritis, 20. 163-7.
- Vertebra:** angioma of, 14. 166.
- Vertebral body:** fracture of, 14. 166.
- Vioform:** 15. 7.
- Vitamin B₁ (Aneurin, Thiamine):** 15. 100, 102, 16. 48, 53, 19. 329-37.
- Vitamin B₁₂:** 20. 196, 199-200.
- Vitamin C:** 13. 23.
- Vitamin D:** 16. 33, 40-44, 17. 203-26, 19. 75-83, 91.
- Vomiting:** from salicylates, 17. 157-8.
- Von Recklinghausen's disease:** 18. 93-103.
- Wassermann reaction:** in ankylosing spondylitis, 18. 223-4; in chronic haemolytic anaemia with cold agglutinins, 20. 285, 288.
- Water deficiency:** after haematemesis, 11. 89-90.
- **diuresis in man:** effect of smoking on, 18. 51-55.
- Wernicke's encephalopathy:** 19. 327-38.
- Xanthomatosis:** honeycomb lungs in, 18. 1-4.
- X-ray sickness:** and antihistamine drugs, 17. 287.
- **therapy:** in thyrotoxicosis, 11. 1-17; iodine and medical treatment during, 11. 4; in spontaneous hypoglycaemia, 19. 26-7.
- X-rays.** *See* Radiological appearances.
- Yatren:** 15. 6-7.
- Yeast extract:** and tropical sprue, 16. 105-7; and megaloblastic anaemia of pregnancy, 20. 196-7, 200.
- Yellow atrophy:** 20. 425, 428-30; *see also* Liver, massive necrosis of the.
- Zinc oxide poisoning:** in industry, 12. 187.

Ac

88

,
,
-
g
-
.
.
.
.,
.,
3.
3.
3.
3,
;
3,
9.
.
6.
of
0
2.